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With recent advances in various high throughput technologies, the rise of omics data 
offers a promise of personalized health care with its potential to expand both the depth 
and the width of the identification of risk factors that are associated with human complex 
traits. In genomics, the introduction of repeated measures and the increased sequencing 
depth provides an opportunity for deeper investigation of disease dynamics for patients. 
In transcriptomics, high throughput single-cell assays provide cellular level gene 
expression depicting cell-to-cell heterogeneity. The cell-level resolution of gene 
expression data brought the opportunities to promote our understanding of cell function, 
disease pathogenesis, and treatment response for more precise therapeutic development. 
Along with these advances are the challenges posed by the increasingly complicated data 
sets. In genomics, as repeated measures of phenotypes are crucial for understanding the 
onset of disease and its temporal pattern, longitudinal designs of omics data and 
phenotypes are being increasingly introduced. However, current statistical tests for 
longitudinal outcomes, especially for binary outcomes, depend heavily on the correct 
specification of the phenotype model. As many diseases are rare, efficient designs are 
commonly applied in epidemiological studies to recruit more cases. Despite the enhanced 
efficiency in the study sample, this non-random ascertainment sampling can be a major 
source of model misspecification that may lead to inflated type I error and/or power loss 
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in the association analysis. In transcriptomics, the analysis of single-cell RNA-seq data is 
facing its particular challenges due to low library size, high noise level, and prevalent 
dropout events. The purpose of this dissertation is to provide the methodological 
foundation to tackle the aforementioned challenges. We first propose a set of 
retrospective association tests for the identification of genetic loci associated with 
longitudinal binary traits. These tests are robust to different types of phenotype model 
misspecification and ascertainment sampling design which is common in longitudinal 
cohorts. We then extend these retrospective tests to variant-set tests for genetic rare 
variants that have low detection power by incorporating the variance component test and 
burden test into the retrospective test framework. Finally, we present a novel gene-graph 
based imputation method to impute dropout events in single-cell transcriptomic data to 
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Single-SNP Retrospective Association Tests 
For Longitudinal Binary Traits 
1.1 Abstract 
Longitudinal phenotypes have been increasingly available in genome-wide 
association studies (GWAS) and electronic health record-based studies for identification 
of genetic variants that influence complex traits over time. For longitudinal binary data, 
there remain significant challenges in gene mapping, including misspecification of the 
model for the phenotype distribution due to ascertainment. Here, we propose L-BRAT, a 
retrospective, generalized estimating equations-based method for genetic association 
analysis of longitudinal binary outcomes. We also develop RGMMAT, a retrospective, 
generalized linear mixed model-based association test. Both tests are retrospective score 
approaches in which genotypes are treated as random conditional on phenotype and 
covariates. They allow both static and time-varying covariates to be included in the 
analysis. Through simulations, we illustrated that retrospective association tests are 
robust to ascertainment and other types of phenotype model misspecification, and gain 
power over previous association methods. We applied L-BRAT and RGMMAT to a 
genome-wide association analysis of repeated measures of cocaine use in a longitudinal 
cohort. Pathway analysis implicated association with opioid signaling and axonal 
guidance signaling pathways. Lastly, we replicated important pathways in an independent 
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cocaine dependence case-control GWAS. Our results illustrate that L-BRAT is able to 
detect important loci and pathways in a genome scan and to provide insights into genetic 
architecture of cocaine use. 
1.2 Introduction 
Genome-wide association studies (GWAS) have successfully discovered many 
disease susceptibility loci and provided insights into the genetic architecture of numerous 
human complex diseases and traits. In some genetic epidemiological studies, 
longitudinally collected phenotype data are available. This is the case for many electronic 
health record (EHR)-based studies. As many of these studies continue to follow enrolled 
subjects (e.g. the UK Biobank (UKB) and the Million Veteran Program (MVP)), 
longitudinal phenotypes will be increasingly available with the passage of time, providing 
new data resources that require appropriate analytical tools for optimal analysis. Standard 
association tests that consider one time point or collapse repeated measurements into a 
single value such as an average do not capture the trajectory of phenotypic traits over 
time and may result in a loss of statistical power to detect genetic associations. In 
addition, the effects of time-varying covariates cannot be easily incorporated in such 
analyses. Recently, methodological developments for GWAS have proliferated to make 
full use of the available longitudinal data. For population cohorts, methods that account 
for dependence among observations from an individual include mixed effects models 
[1,2], generalized estimating equations (GEE) [3], growth mixture models[4,5], and 
empirical Bayes models [6]. Most of these approaches are prospective analyses and have 
been successfully applied to quantitative phenotypes. 
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As many diseases are rare, efficient designs, such as the case-control design, are 
commonly applied in epidemiological studies to recruit study subjects. Despite the 
enhanced efficiency in the study sample, non-random ascertainment can be a major 
source of model misspecification that may lead to inflated type I error and/or power loss 
in association analysis. The linear mixed model and the logistic mixed model do not 
perform well when the case-control ratio is unbalanced in large-scale genetic association 
studies [7]. Prospective analysis in which a population-based model is used ignores 
ascertainment bias and can result in compromised statistical inference. Furthermore, in 
the ascertained sample, the prospective approach conditional on the genotype and 
covariates may lose information when the joint distribution of the genotype and 
covariates carries additional information on whether the phenotype is associated with the 
genotype [8]. In this regard, several retrospective association methods have been 
proposed for analyzing ascertained population-based case-control studies [9,10], family-
based studies of continuous traits [11], family-based case-control studies [12,13], and 
family-based longitudinal quantitative traits [14]. Compared to prospective tests, 
retrospective tests conditional on the phenotype and covariates are more robust to 
misspecification of the trait model[8].  
To generalize case-control sampling, outcome-dependent sampling designs have 
become popular for binary data in longitudinal cohort studies [15–17]. However, 
association tests for longitudinally measured binary data are less well developed in 
GWAS. Here, we propose L-BRAT, a retrospective, GEE-based method for genetic 
association analysis of longitudinal binary outcomes. It requires specification of the mean 
of the outcome distribution and a working correlation matrix for repeated measurements. 
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L-BRAT is a retrospective score approach in which genotypes are treated as random 
conditional on the phenotype and covariates. Thus, it is robust to ascertainment and trait 
model misspecification. It allows both static and time-varying covariates to be included 
in the analysis. We note that GMMAT, a recently proposed prospective test using the 
logistic mixed model to control for population structure and cryptic relatedness in case-
control studies [18], can be adapted for repeated binary data. For comparison, we also 
develop RGMMAT, a retrospective, generalized linear mixed model (GLMM)-based 
association test for longitudinal binary traits. 
We performed simulation studies to evaluate the type I error and power of L-BRAT 
and RGMMAT, and compared them to the existing prospective methods. The results 
demonstrate that the retrospective association tests have better control of type I error 
when the phenotype model is misspecified, and are robust to various ascertainment 
schemes. Moreover, they are more powerful than the prospective tests. Finally, we 
applied L-BRAT and RGMMAT to a genome-wide association analysis of repeated 
measurements of cocaine use in a longitudinal cohort, the Veterans Aging Cohort Study 
(VACS), and replicated the results using data from an independent cocaine dependence 
case-control GWAS. 
 
1.3 Materials and methods 
Suppose a binary trait is measured over time on a study population of 𝑛𝑛 individuals. 
We have their genome-wide measures of genetic variation. A set of covariates, static or 
dynamic, are also available. Let 𝑛𝑛𝑖𝑖 be the number of repeated measures on individual 𝛽𝛽 
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and 𝑁𝑁 = ∑ 𝑛𝑛𝑖𝑖𝑛𝑛𝑖𝑖=1  be the total number of observations. For individual 𝛽𝛽, let 𝑿𝑿𝑖𝑖𝑖𝑖 and 𝑌𝑌𝑖𝑖𝑖𝑖 be 
the 𝑝𝑝-dimensional covariate vector, assumed to include an intercept, and the binary 
response at time 𝑡𝑡𝑖𝑖𝑖𝑖, respectively. In this setting, individuals are permitted to have 
measurements at different time points and different number of observations. We let 𝒀𝒀 
denote the outcome vector of length 𝑁𝑁, and let 𝑿𝑿 denote the 𝑁𝑁 × 𝑝𝑝 covariate matrix. 
Here, we focus on the problem of testing for association between a genetic variant and 
the longitudinal binary outcomes. Let 𝑮𝑮 denote the vector of genotypes for the 𝑛𝑛 
individuals at the variant to be tested, where 𝐺𝐺𝑖𝑖 = 0, 1, or 2 is the number of minor alleles 
of individual 𝛽𝛽 at the variant. 
1.3.1 Generalized estimating equations (GEE) model 
We consider a GEE approach in which the mean of the outcome distribution, given 
the genotype and covariates, is specified as 
𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � 𝑮𝑮,𝑿𝑿� = 𝜇𝜇𝑖𝑖𝑖𝑖 ,   logit �𝜇𝜇𝑖𝑖𝑖𝑖� = 𝑿𝑿𝑖𝑖𝑖𝑖𝑇𝑇 𝜷𝜷 + 𝐺𝐺𝑖𝑖𝛾𝛾,   𝛽𝛽 = 1, … ,𝑛𝑛;  𝑗𝑗 = 1, … ,𝑛𝑛𝑖𝑖 ,              (1) 
where 𝜷𝜷 is a 𝑝𝑝-dimensional vector of covariate effects and 𝛾𝛾 is a scalar parameter of 
interest representing the effect of the tested variant. Writing in a matrix form, we have the 
mean model 
𝐸𝐸(𝒀𝒀 | 𝑮𝑮,𝑿𝑿) = 𝝁𝝁,   logit (𝝁𝝁) = 𝑿𝑿𝜷𝜷 + 𝑩𝑩𝑮𝑮𝛾𝛾,                                     (2) 
where 𝑩𝑩 is an 𝑁𝑁 × 𝑛𝑛 matrix representing the measurement clustering structure, and its 
(𝑙𝑙, 𝛽𝛽)th entry 𝐵𝐵𝑙𝑙𝑖𝑖 is an indicator of the 𝑙𝑙th entry of 𝒀𝒀 being a measurement on individual 𝛽𝛽. 
Here, the vector 𝑩𝑩𝑮𝑮 is the vertically expanded genotype vector that maps the genotype 
data 𝑮𝑮 from the individual level to the measurement level. The covariance structure of 𝒀𝒀 
is given by 
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Var(𝒀𝒀 | 𝑮𝑮,𝑿𝑿) = 𝚪𝚪1/2𝚺𝚺𝚪𝚪1/2,                                                 (3) 
where 𝚪𝚪 = diag�𝜇𝜇1,1�1 − 𝜇𝜇1,1�, … , 𝜇𝜇1,𝑛𝑛1�1 − 𝜇𝜇1,𝑛𝑛1�, … , 𝜇𝜇𝑛𝑛,1�1 − 𝜇𝜇𝑛𝑛,1�, … , 𝜇𝜇𝑛𝑛,𝑛𝑛𝑛𝑛�1 −
𝜇𝜇𝑛𝑛,𝑛𝑛𝑛𝑛�� is an 𝑁𝑁-dimensional diagonal matrix and 𝚺𝚺 is an 𝑁𝑁 × 𝑁𝑁 correlation matrix. The 
covariance specification in Eq. (3) ensures that the variance of the dichotomous response 
𝑌𝑌𝑖𝑖𝑖𝑖 depends on its mean in a way that is consistent with the Bernoulli distribution. To 
apply the GEE method, a working correlation structure such as independent, 
exchangeable, and first-order autoregressive (AR(1)) must be specified. For a given 
within-cluster correlation matrix 𝚺𝚺(𝜏𝜏), which may depend on some parameter 𝜏𝜏, the 







To detect association between the genetic variant and the phenotype, we consider a 
score approach to test 𝐻𝐻0: 𝛾𝛾 = 0 against 𝐻𝐻1: 𝛾𝛾 ≠ 0. The null estimate of 𝜷𝜷, denoted by 
𝜷𝜷�0, is the solution to a system of estimating equations 𝑼𝑼(𝜷𝜷) = 0 under the constraint 𝛾𝛾 =
0, which can be computed iteratively between a Fisher scoring algorithm for 𝜷𝜷 and the 
method of moments for 𝜏𝜏 until convergence. Then, the score function for 𝛾𝛾 is 
𝑈𝑈0 = 𝑈𝑈(𝛾𝛾)|𝜷𝜷�0,0,𝜏𝜏�0 = (𝑩𝑩𝑮𝑮)
𝑇𝑇𝚪𝚪�0
1/2𝚺𝚺�0−1𝚪𝚪�0
−1/2(𝒀𝒀 − 𝝁𝝁�0),                             (4) 
where 𝝁𝝁�0, 𝚪𝚪�0 and 𝚺𝚺�0 are 𝝁𝝁, 𝚪𝚪 and 𝚺𝚺 evaluated at (𝜷𝜷, 𝛾𝛾, 𝜏𝜏) = �𝜷𝜷�0, 0, ?̂?𝜏0�. 











 ,                             (5) 
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where the null variance of 𝑈𝑈0 is evaluated using a robust sandwich variance estimator, 





1/2 and the sample covariance of 𝒀𝒀, Cov� (𝒀𝒀), is 
estimated by (𝒀𝒀 − 𝝁𝝁�0)(𝒀𝒀 − 𝝁𝝁�0)𝑇𝑇. Under the null hypothesis, the 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺 test statistic has an 
asymptotic 𝜒𝜒12 distribution.  
1.3.2 L-BRAT retrospective test 
In what follows, we introduce a new GEE-based association testing method, L-BRAT 
(Longitudinal Binary-trait Retrospective Association Test). The L-BRAT test statistic is 
also based on the score function 𝑈𝑈0 in Eq. (4). In contrast to the prospective GEE score 
test, L-BRAT takes a retrospective approach in which the variance of 𝑈𝑈0 is assessed 
using a retrospective model of the genotype given the phenotype and covariates. An 
advantage of the retrospective approach is that the analysis is less dependent on the 
correct specification of the phenotype model. We assume that under the null hypothesis 
of no association between the genetic variant and the phenotype, the quasi-likelihood 
model of 𝑮𝑮 conditional on 𝒀𝒀 and 𝑿𝑿 is 
𝐸𝐸0(𝑮𝑮 | 𝒀𝒀,𝑿𝑿) = 2𝑝𝑝𝟏𝟏𝑛𝑛,   Var0(𝑮𝑮 | 𝒀𝒀,𝑿𝑿) = 𝜎𝜎𝑔𝑔2𝚽𝚽,                                   (6) 
where 𝑝𝑝 is the minor allele frequency (MAF) of the tested variant, 𝟏𝟏𝑛𝑛 is a vector of 
length 𝑛𝑛 with every element equal to 1, 𝜎𝜎𝑔𝑔2 is an unknown variance parameter, and 𝚽𝚽 is 
an 𝑛𝑛 × 𝑛𝑛 genetic relationship matrix (GRM) representing the overall genetic similarity 
between individuals due to population structure. Because 𝑩𝑩𝟏𝟏𝑛𝑛 = 𝟏𝟏𝑁𝑁, which is the first 
column of 𝑿𝑿 that encodes an intercept, and 𝚪𝚪�0
1/2𝚺𝚺�0−1𝚪𝚪�0
−1/2(𝒀𝒀 − 𝝁𝝁�0), the 𝑁𝑁-dimensional 
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vector of transformed null phenotypic residuals, is orthogonal to the column space of 𝑿𝑿, 
then the null mean model of 𝑮𝑮 in Eq. (6) ensures that 
𝐸𝐸0(𝑈𝑈0 | 𝒀𝒀,𝑿𝑿) = 𝐸𝐸0(𝑨𝑨𝑇𝑇𝑮𝑮 | 𝒀𝒀,𝑿𝑿) = 2𝑝𝑝𝑨𝑨𝑇𝑇𝟏𝟏𝑛𝑛 = 0, 
where 𝑨𝑨 = 𝑩𝑩𝑇𝑇𝚪𝚪�0
1/2𝚺𝚺�0−1𝚪𝚪�0
−1/2(𝒀𝒀 − 𝝁𝝁�0) is the individual-level transformed phenotypic 
residual vector of length 𝑛𝑛. 











where 𝐾𝐾 is the total number of genotyped variants, 𝑮𝑮(𝑘𝑘) is the genotype vector at the 𝑘𝑘th 
variant, and ?̂?𝑝𝑘𝑘 is the estimated MAF, for example, ?̂?𝑝𝑘𝑘 = ?̅?𝐺𝑘𝑘/2, the sample MAF at the 
𝑘𝑘th variant. For the variant of interest, let ?̂?𝑝 = ?̅?𝐺/2 be its sample MAF. Under Hardy-
Weinberg equilibrium, the variance of the genotype is estimated by 𝜎𝜎�𝑔𝑔2 = 2?̂?𝑝(1 − ?̂?𝑝). Or 
we can use a more robust variance estimator (Jakobsdottir and McPeek 2013) given by 
𝜎𝜎�𝑔𝑔2 = (𝑛𝑛 − 1)−1𝑮𝑮𝑇𝑇𝑾𝑾𝑮𝑮, 
where 𝑾𝑾 = 𝚽𝚽−1 −𝚽𝚽−1𝟏𝟏𝑛𝑛(𝟏𝟏𝑛𝑛𝑇𝑇𝚽𝚽−1𝟏𝟏𝑛𝑛)−1𝟏𝟏𝑛𝑛𝑇𝑇𝚽𝚽−1. Finally, the L-BRAT test statistic can 












 .                         (7) 
Under regularity conditions, L-BRAT asymptotically follows a 𝜒𝜒12 distribution under the 
null hypothesis. 
1.3.3 Generalized linear mixed model (GLMM) 
The Generalized linear Mixed Model Association Test (GMMAT) was originally 
designed to use random effects in logistic mixed models to account for population 
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structure and cryptic relatedness in case-control studies[18].To extend the GMMAT 
method for case-control analysis to repeated binary data, we consider the following 
logistic mixed model: 
logit �𝜇𝜇𝑖𝑖𝑖𝑖� = 𝑿𝑿𝑖𝑖𝑖𝑖𝑇𝑇 𝜷𝜷 + 𝐺𝐺𝑖𝑖𝛾𝛾 + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 ,   𝛽𝛽 = 1, … ,𝑛𝑛;  𝑗𝑗 = 1, … ,𝑛𝑛𝑖𝑖 ,                            (8) 
where 𝜇𝜇𝑖𝑖𝑖𝑖 = 𝑃𝑃�𝑌𝑌𝑖𝑖𝑖𝑖 = 1 � 𝐺𝐺𝑖𝑖 ,𝑿𝑿𝑖𝑖𝑖𝑖 ,𝑎𝑎𝑖𝑖 , 𝑟𝑟𝑖𝑖𝑖𝑖� is the probability of a binary response at time 𝑡𝑡𝑖𝑖𝑖𝑖 
for individual 𝛽𝛽, conditional on his/her genotype, covariates, and random effects 𝑎𝑎𝑖𝑖 and 
𝑟𝑟𝑖𝑖𝑖𝑖, 𝜷𝜷 and 𝛾𝛾 are the same as defined in model (1), 𝑎𝑎𝑖𝑖 is the individual random effect, and 
𝑟𝑟𝑖𝑖𝑖𝑖 is the individual-specific time-dependent random effect. The two random effects were 
used to capture the correlation among repeated measures in gene-based association test 
for longitudinal traits [19]. Here, 𝑎𝑎𝑖𝑖 's are assumed to be independent and 𝑎𝑎𝑖𝑖 ∼ 𝑁𝑁(0,𝜎𝜎𝑎𝑎2). 
The vector of time-dependent random effects 𝒓𝒓𝑖𝑖 = (𝑟𝑟𝑖𝑖1, … , 𝑟𝑟𝑖𝑖,𝑛𝑛𝑖𝑖) has a multivariate 
normal distribution, 𝒓𝒓𝑖𝑖 ∼ 𝑀𝑀𝑀𝑀𝑁𝑁(𝟎𝟎,𝜎𝜎𝑟𝑟2𝑹𝑹𝑖𝑖), where an AR(1) structure is assumed for the 
correlation matrix 𝑹𝑹𝑖𝑖, in which 𝜏𝜏 is the unknown parameter. The binary responses 𝑌𝑌𝑖𝑖𝑖𝑖 are 
assumed to be independent given the random effects 𝑎𝑎𝑖𝑖 and 𝑟𝑟𝑖𝑖𝑖𝑖. Note that the first 
relatedness matrix of the random effects in the original GMMAT paper is genetic 
relationship matrix, but in our model for the longitudinal data, the two relatedness 
matrices correspond to the individual random effect and the individual specific time-
dependent random effect.  
To construct a score test for the null hypothesis 𝐻𝐻0: 𝛾𝛾 = 0 vs. the alternative 𝐻𝐻1: 𝛾𝛾 ≠
0, we use the penalized quasi-likelihood method [20] to fit the null logistic mixed model 
and obtain the null estimates of 𝜷𝜷,𝜎𝜎𝑎𝑎2,𝜎𝜎𝑟𝑟2 and 𝜏𝜏, denoted by 𝜷𝜷�0,𝜎𝜎�𝑎𝑎2,𝜎𝜎�𝑟𝑟2 and ?̂?𝜏0 [18]. 
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Similarly, the best linear unbiased predictor (BLUP) of random effects, 𝒂𝒂� and 𝒓𝒓�, can be 
obtained. Then, the resulting score function for 𝛾𝛾 is 
𝑆𝑆0 = 𝑆𝑆(𝛾𝛾)|𝜷𝜷�0,0,𝜎𝜎�𝑎𝑎2,𝜎𝜎�𝑟𝑟2,𝜏𝜏�0,𝒂𝒂�,𝒓𝒓� = (𝑩𝑩𝑮𝑮)
𝑇𝑇(𝒀𝒀 − 𝝁𝝁�0),                                         (9) 
where 𝝁𝝁�0 = logit−1(𝑿𝑿𝜷𝜷�0 + 𝑩𝑩𝒂𝒂� + 𝒓𝒓�) is a vector of fitted values under 𝐻𝐻0. 
In GMMAT, the null variance of the score 𝑆𝑆0 is evaluated prospectively [18], i.e., 
Var0(𝑆𝑆0 | 𝑮𝑮,𝑿𝑿) = (𝑩𝑩𝑮𝑮)𝑇𝑇𝑷𝑷𝑩𝑩𝑮𝑮, where 𝑷𝑷 = 𝚿𝚿−1 −𝚿𝚿−1𝑿𝑿(𝑿𝑿𝑇𝑇𝚿𝚿−1𝑿𝑿)−1𝑿𝑿𝑇𝑇𝚿𝚿−1, and 𝚿𝚿 =
𝚪𝚪�0−1 + 𝜎𝜎�𝑎𝑎2𝑩𝑩𝑩𝑩𝑇𝑇 + 𝜎𝜎�𝑟𝑟2𝑹𝑹�. Here 𝚪𝚪�0 and 𝑹𝑹� are 𝚪𝚪 and 𝑹𝑹 evaluated at (𝜷𝜷, 𝛾𝛾,𝜎𝜎𝑎𝑎2,𝜎𝜎𝑟𝑟2, 𝜏𝜏) =
�𝜷𝜷�0, 0,𝜎𝜎�𝑎𝑎2,𝜎𝜎�𝑟𝑟2, ?̂?𝜏0�, where 𝚪𝚪 is the same as defined in Eq. (3) and 𝑹𝑹 = diag{𝑹𝑹1, … ,𝑹𝑹𝑛𝑛} is 








 .                                         (10) 
1.3.4 RGMMAT retrospective test 
Like L-BRAT, we can construct a retrospective test to assess the significance of the 
GLMM score function of Eq. (9), which we call RGMMAT, based on the quasi-












 ,                              (11) 
where 𝑪𝑪 = 𝑩𝑩𝑇𝑇(𝒀𝒀 − 𝝁𝝁�0) is the 𝑛𝑛-dimensional vector of phenotypic residuals at the 
individual level by summing over all time points for an individual, and the phenotypic 
residuals are obtained by fitting the null logistic mixed model. Both the GMMAT and 
RGMMAT test statistics are assumed to have 𝜒𝜒12 asymptotic null distributions. 
1.3.5 Simulation studies 
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We performed simulation studies to evaluate the type I error and power of the two 
retrospective tests we propose, and compared them to the prospective GEE and GMMAT 
methods. We also assessed sensitivity of L-BRAT and RGMMAT in the presence of 
model misspecification and ascertainment. In the simulations, we considered two 
different trait models and three different ascertainment schemes. Because both the L-
BRAT and GEE methods require specification of a working correlation matrix, we 
implemented three working correlation structures: (1) independent, (2) AR(1), and (3) a 
mixture of exchangeable and AR(1). 
To generate genotypes, we first simulated 10,000 chromosomes over a 1 Mb region 
using a coalescent model that mimics the linkage disequilibrium (LD) and recombination 
rates of the European population [21]. We then randomly selected 1,000 non-causal 
single nucleotide polymorphisms (SNPs) with MAF > 0.05. In addition, we generated 
two causal SNPs that were assumed to influence the trait value with epistasis. In the type 
I error simulations, we tested association at the 1,000 non-causal SNPs. In each 
simulation setting, we generated 1,000 sets of phenotypes at five time points. Putting 
together, 106 replicates were used for the type I error evaluation. In the power 
simulations, we tested the first of the two causal SNPs and empirical power was assessed 
using 1,000 simulation replicates. In all tests considered, the genotypes at the untested 
causal SNP(s) were assumed to be unobserved. 
Trait models 
We simulated two types of binary trait models at five time points, in which the two 
unlinked causal SNPs were assumed to act on the phenotype epistatically. The first type 
is a logistic mixed model, given by 
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𝑌𝑌𝑖𝑖𝑖𝑖|𝑿𝑿𝑖𝑖𝑖𝑖 ,𝐺𝐺𝑖𝑖(1),𝐺𝐺𝑖𝑖(2),𝑎𝑎𝑖𝑖 , 𝑟𝑟𝑖𝑖𝑖𝑖 ∼ Bernoulli �𝜇𝜇𝑖𝑖𝑖𝑖�, 
logit �𝜇𝜇𝑖𝑖𝑖𝑖� = −2.5 + 0.2(𝑗𝑗 − 1) + 0.5𝑋𝑋𝑖𝑖𝑖𝑖(1) + 0.5𝑋𝑋𝑖𝑖(2) + 𝜃𝜃1�𝐺𝐺𝑖𝑖(1)>0,𝐺𝐺𝑖𝑖(2)>0� + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 , 
where 𝑋𝑋𝑖𝑖𝑖𝑖(1) is a continuous, time-varying covariate generated independently from a 
standard normal distribution, 𝑋𝑋𝑖𝑖(2) is a binary, time-invariant covariate taking values 0 or 
1 with a probability of 0.5, 𝐺𝐺𝑖𝑖(1) and 𝐺𝐺𝑖𝑖(2) are the genotypes of individual 𝛽𝛽 at the two 
causal SNPs, 𝜃𝜃 is a scalar parameter encoding the effect of the causal SNPs, 
1�𝐺𝐺𝑖𝑖(1)>0,𝐺𝐺𝑖𝑖(2)>0� is an indicator function that takes value 1 when individual 𝛽𝛽 has at least 
one copy of the minor allele at both the causal SNPs, 𝑎𝑎𝑖𝑖 and 𝑟𝑟𝑖𝑖𝑖𝑖 are the individual-level 
time-independent and time-dependent random effects, respectively. Here we assume 𝑎𝑎𝑖𝑖 ∼
𝑁𝑁(0,  𝜎𝜎𝑎𝑎2) and 𝒓𝒓𝑖𝑖 = (𝑟𝑟𝑖𝑖1, … , 𝑟𝑟𝑖𝑖5) ∼ 𝑀𝑀𝑀𝑀𝑁𝑁(𝟎𝟎,𝜎𝜎𝑟𝑟2𝑹𝑹), where 𝑹𝑹 is a 5 × 5 correlation matrix 
specified by the AR(1) structure with a correlation coefficient 𝜏𝜏. The two causal SNPs are 
assumed to be unlinked with MAFs 0.1 and 0.5, respectively. The variance components 
are set to 𝜎𝜎𝑎𝑎2 = 𝜎𝜎𝑟𝑟2 = 0.64 and 𝜏𝜏 = 0.7. 
The second type of trait model we considered is a liability threshold model in which 
an underlying continuous liability determines the outcome value based on a threshold. 
Specifically, the phenotype 𝑌𝑌𝑖𝑖𝑖𝑖 is given by 
𝑌𝑌𝑖𝑖𝑖𝑖 = 1 if 𝐿𝐿𝑖𝑖𝑖𝑖 > 0, 
with 𝐿𝐿𝑖𝑖𝑖𝑖 = −2.0 + 0.2(𝑗𝑗 − 1) + 0.5𝑋𝑋𝑖𝑖𝑖𝑖(1) + 0.5𝑋𝑋𝑖𝑖(2) + 𝜃𝜃1�𝐺𝐺𝑖𝑖(1)>0,𝐺𝐺𝑖𝑖(2)>0� + 𝑎𝑎𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖
+ 𝑒𝑒𝑖𝑖𝑖𝑖 , 
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where 𝐿𝐿𝑖𝑖𝑖𝑖 is the underlying liability for individual 𝛽𝛽 at time 𝑡𝑡𝑖𝑖𝑖𝑖, and 𝑒𝑒𝑖𝑖𝑖𝑖 ∼ 𝑁𝑁(0,𝜎𝜎𝑒𝑒2) 
represents independent noise, with 𝜎𝜎𝑒𝑒2 = 0.64. All other parameters are the same as those 
in the logistic mixed model. 
In both models, we included a time effect and assumed that the mean of the outcome 
increases with time. The effect of the causal SNPs was set to 𝜃𝜃 = 0.34 in the type I error 
simulations. For the power evaluation, we considered a range of values for 𝜃𝜃, where we 
set 𝜃𝜃 = 0.3, 0.32, 0.34, 0.36, and 0.38. At the given parameter values, the prevalence of 
the event of interest ranges from 12.8% to 27.7% over time. The proportion of the 
phenotypic variance explained by the two causal SNPs ranges from 0.69% to 1.10% in 
the logistic mixed model, and from 0.49% to 0.78% in the liability threshold model. 
Sampling designs 
We considered three different sampling designs. In the “random” sampling scheme, 
the sample contains 2,000 individuals that were randomly selected from the population 
regardless of their phenotypes. Thus, ascertainment is population based. In the “baseline” 
sampling scheme, we sampled 1,000 case subjects and 1,000 control subjects according 
to their outcome value at baseline only. In the “sum” sampling scheme, individuals were 
stratified into three strata (1, 2, and 3) based on a total count that sums each subject’s 
response over time, where samples in stratum 1 never experienced the event of interest, 
i.e., ∑ 𝑌𝑌𝑖𝑖𝑖𝑖𝑖𝑖 = 0, samples in stratum 2 sometimes experienced the event, i.e., 0 < ∑ 𝑌𝑌𝑖𝑖𝑖𝑖𝑖𝑖 <
𝑛𝑛𝑖𝑖, and samples in stratum 3 always experienced the event, i.e., ∑ 𝑌𝑌𝑖𝑖𝑖𝑖𝑖𝑖 = 𝑛𝑛𝑖𝑖. Following 
the outcome-dependent sampling design for longitudinal binary data [17], we selected 
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100, 1,800, and 100 individuals from the three strata respectively to oversample subjects 
who have response variation over the course of the study. 
1.3.6 Application to cocaine use data from VACS 
We illustrated the utility of our proposed methods by analyzing a GWAS dataset of 
cocaine use from VACS [22]. VACS is a multi-center, longitudinal observational study 
of HIV infected and uninfected veterans whose primary objective is to understand the 
risk of alcohol and other substance abuse in individuals with HIV infection. We analyzed 
longitudinal cocaine use in patient surveys collected at six clinic visits on 2,470 
participants. Among them, 69.8% are African Americans (AAs), 19.3% are European 
Americans (EAs), and 10.9% are of other races. We considered the responses at each 
visit as 0 if individuals had never tried cocaine or had not used cocaine in the last year, 
and as 1 if individuals had used cocaine in the last year. The proportion of case subjects 
at each visit ranges from 13.7% (𝑛𝑛 = 192) to 24.3% (𝑛𝑛 = 526), and the missing rate at 
each visit ranges from 3.0% to 44.2%. 
All samples were genotyped on the Illumina OmniExpress BeadChip. After data 
cleaning, there are 2,458 individuals available for genotype imputation. IMPUTE2 [23] 
was used for imputation using the 1000 Genomes Phase 3 data as a reference panel. We 
excluded subjects who did not meet either of the following criteria: (1) completeness (i.e., 
proportion of successfully imputed SNPs) > 95% and (2) empirical self-kinship < 0.525 
(i.e., empirical inbreeding coefficient < 0.05). Based on the above criteria, 2,231 
individuals were retained in the analysis, with 2,114 males and 117 females, of whom 
1,557 are AAs, 431 are EAs, and 243 are of other races. There are 1,433 individuals who 
had never used cocaine during the study period, 639 individuals who sometimes used 
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cocaine, i.e., exhibited response variation, and 159 individuals who had used cocaine at 
least once every year over the course of the study. SNPs that satisfied all of the following 
quality-control conditions were included in the analysis: (1) call rate > 95%, (2) Hardy-
Weinberg 𝜒𝜒2 statistic P-value > 10-6, and (3) MAF > 1%. All together there are a final set 
of 10,215,072 SNPs retained in the analysis. The VACS dataset, both the genotype file in 
the plink format and the phenotype files including the longitudinally measured cocaine 
use and the covariates, will be deposited to dbGap (https://www.ncbi.nlm.nih.gov/gap).  
Pathway and enrichment analyses 
We then performed pathway analysis on the top SNPs for which at least one of the 
longitudinal tests had a P-value < 5 × 10−5 using the Ingenuity Pathway Analysis (IPA). 
The Ingenuity database gathers information from manually reviewed literature, as well as 
large public databases. In this analysis, the top SNPs’ RSID were uploaded into the IPA 
and mapped, if possible, to the reference set in the Ingenuity knowledge. The IPA 
performs a Fisher’s Exact test to determine whether the submitted SNP list belongs to 
genes of a particular function annotation more than expected by chance. We report below 
both Fisher’s exact test P-value and adjusted P-value using Benjamini-Hochberg method 
for multiple testing adjusting for the number of ontologies tested. We consider pathways 
with adjusted P-value less than 0.05 to be significant.  We also performed an enrichment 
analysis to see whether the top SNPs in our analysis are more likely to regulate brain 
gene expression.  
Replication data 
We used an independent cocaine dependence case-control GWAS from the Yale-
Penn study [24] to replicate the top findings from our longitudinal analysis results in 
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VACS. The summary statistics from the Yale-Penn cocaine dependence GWAS were 
obtained. Note that the lifetime cocaine dependence diagnosis was made using the Semi-
Structured Assessment for Drug Dependence and Alcoholism (SSADDA) [25], which is 
different from the outcome used in VACS, and there were no longitudinal phenotype 
measures in Yale-Penn. Pathway analysis using IPA was applied to the summary 
statistics of Yale-Penn on the top SNP list identified from VACS. The Fisher’s exact test 
P-values were calculated for each pathway to evaluate if there were more associated 
SNPs than would be expected by chance. 
1.4 Results 
1.4.1 Type I error assessment 
To assess type I error, we tested for association at unlinked and unassociated SNPs. 
Table 1.1 gives the empirical type I error of the L-BRAT, RGMMAT, GEE, and 
GMMAT tests, based on 106 replicates, at the nominal type I error level 𝛼𝛼, for 𝛼𝛼 = 0.05, 
0.01, 0.001, and 0.0001. In all simulations, the type I error of the two retrospective tests, 
L-BRAT and RGMMAT, exhibited no inflation at any of the nominal levels considered. 
In contrast, the prospective GEE tests, regardless of the choice of working correlation, 
had inflated type I error at most of the nominal levels in all settings. This is likely due to 
the fact that the asymptotic distribution of robust sandwich variance estimators used in 
GEE are not well calibrated. The inflated type I error was also reported in longitudinal 
GWAS with quantitative traits using GEE [3]. In GMMAT, the type I error was much 
lower than the nominal level when 𝛼𝛼 = 0.05, 0.01, 0.001, and 0.0001. These results 
demonstrate that the two retrospective tests, L-BRAT and RGMMAT, are robust to trait 
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model misspecification and ascertainment, whereas GEE has type I error inflation and 
GMMAT is overly conservative. Overall, the choice of the working correlation matrix 
does not have much impact on the type I error of the L-BRAT method. 
Table 1.1. Empirical type I error of L-BRAT, RGMMAT, GEE, and GMMAT, based on 106 
replicates. 
Test Level 
Logistic Mixed Model Liability Threshold Model 
Random Baseline Sum Random Baseline Sum 
GEE 
(ind) 
0.05 5.38 × 10-2 5.08 × 10-2 5.27 × 10-2 5.36 × 10-2 5.19 × 10-2 5.38 × 10-2 
0.01 1.18 × 10-2 1.04 × 10-2 1.13 × 10-2 1.17 × 10-2 1.07 × 10-2 1.17 × 10-2 
0.001 1.32 × 10-3 1.16 × 10-3 1.23 × 10-3 1.37 × 10-3 1.14 × 10-3 1.37 × 10-3 
0.0001 1.67 × 10-4 1.28 × 10-4 1.43 × 10-4 1.34 × 10-4 1.36 × 10-4 1.76 × 10-4 
GEE 
(AR1) 
0.05 5.36 × 10-2 5.02 × 10-2 5.26 × 10-2 5.34 × 10-2 5.17 × 10-2 5.37 × 10-2 
0.01 1.16 × 10-2 1.04 × 10-2 1.12 × 10-2 1.16 × 10-2 1.06 × 10-2 1.17 × 10-2 
0.001 1.31 × 10-3 1.13 × 10-3 1.21 × 10-3 1.36 × 10-3 1.14 × 10-3 1.36 × 10-3 
0.0001 1.73 × 10-4 1.19 × 10-4 1.37 × 10-4 1.32 × 10-4 1.35 × 10-4 1.78 × 10-4 
GEE(mix) 
0.05 5.34 × 10-2 5.07 × 10-2 5.26 × 10-2 5.34 × 10-2 5.19 × 10-2 5.37 × 10-2 
0.01 1.17 × 10-2 1.04 × 10-2 1.13 × 10-2 1.16 × 10-2 1.07 × 10-2 1.17 × 10-2 
0.001 1.29 × 10-3 1.17 × 10-3 1.22 × 10-3 1.38 × 10-3 1.14 × 10-3 1.36 × 10-3 
0.0001 1.70 × 10-4 1.29 × 10-4 1.37 × 10-4 1.31 × 10-4 1.30 × 10-4 1.70 × 10-4 
GMMAT 
0.05 3.89 × 10-2 3.53 × 10-2 4.76 × 10-2 4.80 × 10-2 4.89 × 10-2 4.91 × 10-2 
0.01 6.07 × 10-3 5.24 × 10-3 9.08 × 10-3 9.29 × 10-3 9.51 × 10-3 9.33 × 10-3 
0.001 4.29 × 10-4 3.74 × 10-4 7.84 × 10-4 8.63 × 10-4 8.96 × 10-4 8.33 × 10-4 
0.0001 2.20 × 10-5 2.20 × 10-5 6.80 × 10-5 6.30 × 10-5 9.10 × 10-5 8.80 × 10-5 
L-BRAT 
(ind) 
0.05 4.93 × 10-2 4.91 × 10-2 4.98 × 10-2 5.01 × 10-2 4.99 × 10-2 4.98 × 10-2 
0.01 9.45 × 10-3 9.60 × 10-3 9.84 × 10-3 9.90 × 10-3 9.75 × 10-3 9.55 × 10-3 
0.001 8.30 × 10-4 9.78 × 10-4 9.24 × 10-4 9.55 × 10-4 9.45 × 10-4 8.78 × 10-4 
0.0001 7.20 × 10-5 9.50 × 10-5 8.20 × 10-5 8.20 × 10-5 9.40 × 10-5 9.20 × 10-5 
L-BRAT 0.05 4.93 × 10-2 4.88 × 10-2 4.97 × 10-2 4.99 × 10-2 4.98 × 10-2 4.97 × 10-2 
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(AR1) 0.01 9.48 × 10-3 9.72 × 10-3 9.78 × 10-3 9.84 × 10-3 9.76 × 10-3 9.55 × 10-3 
0.001 8.26 × 10-4 9.62 × 10-4 9.22 × 10-4 9.17 × 10-4 9.47 × 10-4 8.48 × 10-4 
0.0001 8.80 × 10-5 9.60 × 10-5 8.20 × 10-5 7.10 × 10-5 1.02 × 10-4 8.90 × 10-5 
L-BRAT 
(mix) 
0.05 4.93 × 10-2 4.91 × 10-2 4.99 × 10-2 5.01 × 10-2 4.98 × 10-2 4.98 × 10-2 
0.01 9.57 × 10-3 9.61 × 10-3 9.86 × 10-3 9.88 × 10-3 9.79 × 10-3 9.54 × 10-3 
0.001 8.35 × 10-4 9.86 × 10-4 9.26 × 10-4 9.57 × 10-4 9.37 × 10-4 8.78 × 10-4 
0.0001 8.20 × 10-5 1.01 × 10-4 8.60 × 10-5 7.40 × 10-5 9.70 × 10-5 8.90 × 10-5 
RGMMAT 
0.05 4.72 × 10-2 4.91 × 10-2 4.98 × 10-2 4.93 × 10-2 4.99 × 10-2 4.98 × 10-2 
0.01 8.76 × 10-3 9.64 × 10-3 9.85 × 10-3 9.63 × 10-3 9.78 × 10-3 9.55 × 10-3 
0.001 7.20 × 10-4 9.52 × 10-4 9.09 × 10-4 9.12 × 10-4 9.43 × 10-4 8.75 × 10-4 
0.0001 6.80 × 10-5 8.90 × 10-5 8.20 × 10-5 7.70 × 10-5 9.10 × 10-5 9.30 × 10-5 
 
1.4.2 Power comparison 
To compare power, we considered five effect sizes at the two causal SNPs, and tested 
association between the trait and the first causal SNP. Empirical power was calculated at 
the significance level 10-3, based on 1,000 simulated replicates. Figure 1 demonstrates the 
power results for each method. In all the simulation settings, the retrospective tests 
consistently had higher power than the prospective tests. The L-BRAT association tests 
under three different working correlation structures had similar power. The RGMMAT 
method also achieved high power. In contrast, the prospective GEE methods had the 
lowest power in all settings except under the baseline sampling and the liability threshold 
model, in which GMMAT performed the worst in power. Overall, we found that the 
baseline sampling scheme generated the highest power under different trait models, while 
the sum sampling scheme had a power gain over the random sampling scheme under the 
logistic mixed model, but was less powerful under the liability threshold model. These 
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results suggest that L-BRAT and RGMMAT outperform the prospective tests, and the 
power of L-BRAT is not sensitive to the choice of the working correlation structure.  
 
Figure 1.1. Empirical power of L-BRAT, RGMMAT, GEE, and GMMAT. Power is based 
on 1,000 simulated replicates at five time points with 𝛼𝛼 = 10−3. In the upper panel, the trait is 
simulated by the logistic mixed model, and in the lower panel, it is by the liability threshold 
model. Power results are demonstrated in samples of 2,000 individuals according to three 
different ascertainment schemes: random, baseline, and sum. This figure appears in color in the 
electronic version of this article. 
 
1.4.3 Analysis of Longitudinal Cocaine Use Data from VACS 
Genome-wide association testing for longitudinal cocaine use was performed using L-
BRAT, RGMMAT, and the prospective GEE and GMMAT tests in the entire VACS 
sample. Sex, age at baseline, HIV status, and time were included as covariates in the 
analysis. The top ten principal components (PCs) that explained 89.4% of the total 
genetic variation were included as covariates to control for population structure. We 
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considered two working correlation structures: independent and AR(1). For the L-BRAT 
and RGMMAT methods, the GRM was calculated using the LD pruned SNPs with 
MAF > 0.05. 
To compare the performance of longitudinal association analysis with that of 
univariate analysis on the summary metrics of cocaine use in VACS, we considered two 
alternative cocaine phenotypes: baseline and trajectories. Longitudinal cocaine use 
trajectories were obtained using a growth mixture model that clusters longitudinal data 
into discrete growth trajectory curves [26]. We fit a logistic model with a polynomial 
function of time. The number of groups was chosen based on the Bayesian information 
criterion (BIC). Each individual was then assigned to the trajectory with the highest 
probability of membership. Figure 2 shows the four cocaine use trajectory groups 
identified in the VACS sample. They were labeled as mostly never (0, 𝑛𝑛 = 1,682), 
moderate decrease (1, 𝑛𝑛 = 296), elevated chronic (2, 𝑛𝑛 = 86), and mostly frequent (3, 
𝑛𝑛 = 167). We used CARAT, a case-control retrospective association test [10], for the 
analysis of cocaine use at baseline, adjusted for sex, age at baseline, and HIV status. 
Cumulative logit model was used to test for association between the four ordered cocaine 
use trajectory groups and each of the SNPs, with adjustment for sex, age at baseline, HIV 




Figure 1.2. Group-based cocaine use trajectories in VACS. Dashed lines represent the 
estimated trajectories, solid lines represent the observed mean cocaine use for each trajectory 
group. Time is the number of years since the baseline visit. 
 
None of the retrospective tests exhibited evidence of inflation in the quantile-quantile 
(Q-Q) plot. The genomic control inflation factors were 0.993 and 0.991 for the L-BRAT 
genome scan under the independent and AR(1) working correlation, respectively, and 
0.984 for the RGMMAT analysis. The prospective GEE tests showed some evidence of 
deflation in the Q-Q plot. The genomic control factors were 0.938 and 0.937 for the GEE 
tests under the independent and AR(1) working correlation. The most conservative test 
was GMMAT, with a genomic control factor 0.802. 
Table 1.2 reports the results for SNPs for which at least one of the longitudinal tests 
gives a P-value < 2 × 10−7. Among them, the L-BRAT tests produced the smallest P-
values, RGMMAT and the trajectory-based analysis had comparable results, while GEE, 
GMMAT, and CARAT generated much larger P-values. Among the top SNPs listed in 
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Table 1.2, there are two SNPs, rs551879660 and rs150191017, located at 3p12 and 13q12 
respectively, that reach the genome-wide significance (P = 2.00 × 10−8 and 
3.77 × 10−8, respectively). Each of these SNPs was reported to have MAF < 1% in the 
1000 Genomes (MAF = 0.68% and 0.98%, respectively). The MAFs of the two SNPs 
were 1.2% and 1.1% in the entire VACS sample, respectively, and were slightly higher in 
the AA sample (MAF = 1.6% and 1.5%, respectively). Although both SNPs have MAF > 
1%, given the small sample size of VACS, there is limited information on them. SNP 
rs150191017 is located 31.5 kb from the gene AL161616.2 which was reported to be 
associated with venlafaxine treatment response in a generalized anxiety disorder GWAS 
[27]. A cluster of five SNPs in LD, rs76386683, rs114386843, rs186274502, 
rs376616438, and rs187855416, located at 9q33, showed association with longitudinal 
cocaine use (P = 1.85 × 10−7 −  1.93 × 10−7). They are near OR1L4, an olfactory 
receptor gene that was reported to be associated with major depressive disorder [28]. A 
cluster of olfactory receptor genes between OR3A1 and OR3A2 that belong to the 
olfactory receptor gene family were identified in a recent GWAS of cocaine dependence 
and related traits [24]. The other three SNPs, rs188222191, rs1014278, rs75132056, are 
located at 5q21 (P = 1.28 × 10−7, 1.43 × 10−7 and 8.92 × 10−8, respectively), close to 
the gene EFNA5, which was identified in several GWAS to be associated with bipolar 
disorder and schizophrenia [29]. There was also evidence of association with 
rs114629793 (P = 8.65 × 10−8). This SNP is in an intron of the gene encoding PSD3, 
located at 8p22. Recently, two schizophrenia GWAS have identified association between 
PSD3 and schizophrenia [30,31], and one study has shown that PSD3 is associated with 
paliperidone treatment response in schizophrenic patients [32]. Gene network analysis 
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revealed that PSD3 is one of the differentially expressed hub genes that involve 
dysfunction of brain reward circuitry in cocaine use disorder [33].  
Table 1.2. SNPs with P-value < 2×10−7 in at least one of the longitudinal tests in the entire VACS 
sample. The smallest P-value among all tests at the given SNPs are in bold. a CARAT applied to cocaine 
use at baseline, b Cumulative logit model applied to the four ordered cocaine use trajectory group. 













3 NIPA2P2 rs551879660 75,146,492 0.012 1.87 × 10
-4
 7.14 × 10
-4
 9.07 × 10
-4
 2.00 × 10
-8
 3.19 × 10
-6
 4.13 × 10
-5
 5.78 × 10
-4
 3.35 × 10
-5
 
5 EFNA5 rs188222191 105,411,547 0.042 6.86 × 10
-6
 1.65 × 10
-5
 8.87 × 10
-5
 1.28 × 10
-7
 4.17 × 10
-7
 2.69 × 10
-6
 8.95 × 10
-5
 2.72 × 10
-5
 
  rs1014278 105,471,506 0.057 1.02 × 10
-5
 1.10 × 10
-5
 1.24 × 10
-4
 1.50 × 10
-7
 1.43 × 10
-7
 4.88 × 10
-6
 5.94 × 10
-5
 3.00 × 10
-5
 
  rs75132056 105,480,442 0.05 1.05 × 10
-5
 2.42 × 10
-5
 1.89 × 10
-4
 8.92 × 10
-8
 2.89 × 10
-7
 8.55 × 10
-6
 2.59 × 10
-4
 2.31 × 10
-5
 




 1.44 × 10
-4
 8.65 × 10
-8
 3.60 × 10
-7
 2.82 × 10
-6
 5.12 × 10
-4
 3.06 × 10
-6
 
9 OR1L4 rs76386683 125,467,023 0.012 1.48 × 10
-4
 9.15 × 10
-5




 1.93 × 10
-7
 5.92 × 10
-6
 4.80 × 10
-4
 3.30 × 10
-6
 
  rs114386843 125,469,425 0.012 1.47 × 10
-4
 9.05 × 10
-5
 2.82 × 10
-4
 1.01 × 10
-6
 1.88 × 10
-7
 5.78 × 10
-6
 4.75 × 10
-4
 3.22 × 10
-6
 
  rs186274502 125,471,416 0.012 1.47 × 10
-4
 9.05 × 10
-5
 2.82 × 10
-4
 1.01 × 10
-6
 1.88 × 10
-7
 5.78 × 10
-6
 4.75 × 10
-4
 3.22 × 10
-6
 
  rs376616438 125,472,267 0.012 1.44 × 10
-4
 8.95 × 10
-5
 2.77 × 10
-4
 9.79 × 10
-7
 1.85 × 10
-7
 5.62 × 10
-6
 4.79 × 10
-4
 3.20 × 10
-6
 
  rs187855416 125,474,459 0.012 1.44 × 10
-4
 8.95 × 10
-5
 2.77 × 10
-4
 9.79 × 10
-7
 1.85 × 10
-7
 5.62 × 10
-6
 4.79 × 10
-4
 3.20 × 10
-6
 
11 AP000851.1 rs139780693 102,509,700 0.03 2.60 × 10
-5
 1.04 × 10
-5
 2.78 × 10
-4
 5.83 × 10
-7
 1.26 × 10
-7
 1.35 × 10
-5
 1.06 × 10
-4
 2.00 × 10
-6
 
13 AL161616.2 rs150191017 31,962,649 0.011 4.26 × 10
-5
 9.72 × 10
-5
 7.32 × 10
-5
 3.77 × 10
-8
 3.09 × 10
-7
 7.87 × 10
-7
 3.74 × 10
-4




We further analyzed the data separately in each population, adjusted for the top ten 
PCs obtained within the group, and then combined the results from the three groups by 
meta-analysis using the optimal weights for score statistics that have essentially the same 
power as the inverse variance weighting [34]. The results from the three groups (AAs, 
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EAs and other races) were combined by meta-analysis. The meta-analysis P-values were 
of the same order of magnitude as that obtained from the entire sample adjusted for 
population structure for each longitudinal test (Table 1.3). All the top twelve SNPs listed 
in Table 1.3 had a meta-analysis P-value < 8 × 10−7 in at least one of the longitudinal 
tests. Among them, the L-BRAT test with either an independent or AR(1) working 
correlation gave the smallest meta-analysis P-values. 
Table 1.3. Meta-analysis results of the top twelve SNPs from Table 1.2 in the VACS data. The smallest 
P-value among all tests at the given SNPs are in bold. 







3 NIPA2P2 rs551879660 75,146,492 1.81 × 10-4 5.86 × 10-4 8.98 × 10-4 5.26 × 10-8 6.41 × 10-6 6.49 × 10-5 
5 EFNA5 rs188222191 105,411,547 7.57 × 10-6 1.28 × 10-5 1.80 × 10-4 2.55 × 10-7 5.52 × 10-7 1.10 × 10-5 
  rs1014278 105,471,506 1.26 × 10-5 8.44 × 10-6 3.15 × 10-4 1.03 × 10-6 5.59 × 10-7 2.44 × 10-5 
  rs75132056 105,480,442 1.31 × 10-5 2.00 × 10-5 4.24 × 10-4 7.31 × 10-7 1.27 × 10-6 3.56 × 10-5 
8 PSD3 rs114629793 18,403,754 2.92 × 10-4 4.31 × 10-4 1.66 × 10-4 1.79 × 10-7 7.98 × 10-7 6.83 × 10-6 
9 OR1L4 rs76386683 125,467,023 1.44 × 10-4 8.78 × 10-5 3.75 × 10-4 2.32 × 10-6 5.12 × 10-7 1.46 × 10-5 
  rs114386843 125,469,425 1.42 × 10-4 8.62 × 10-5 3.68 × 10-4 2.25 × 10-6 4.97 × 10-7 1.41 × 10-5 
  rs186274502 125,471,416 1.42 × 10-4 8.62 × 10-5 3.68 × 10-4 2.25 × 10-6 4.97 × 10-7 1.41 × 10-5 
  rs376616438 125,472,267 1.39 × 10-4 8.51 × 10-5 3.60 × 10-4 2.18 × 10-6 4.86 × 10-7 1.37 × 10-5 
  rs187855416 125,474,459 1.39 × 10-4 8.51 × 10-5 3.60 × 10-4 2.18 × 10-6 4.86 × 10-7 1.37 × 10-5 
11 AP000851.1 rs139780693 102,509,700 1.15 × 10-5 4.16 × 10-6 1.07 × 10-4 4.04 × 10-7 6.05 × 10-8 4.41 × 10-6 
13 AL161616.2 rs150191017 31,962,649 3.55 × 10-5 6.77 × 10-5 1.26 × 10-4 6.68 × 10-8 5.80 × 10-7 3.12 × 10-6 




Pathway and enrichment analysis results 
We identified two significant canonical pathways that belong to the neurotransmitters 
and nervous system signaling. The first one is the opioid signaling pathway (P =
1.41 × 10−4, adjusted P = 0.010), which plays an important role in opioid tolerance and 
dependence. Studies have shown that chronic administration of cocaine and opioids are 
associated with changes in dopamine transporters and opioid receptors in various brain 
regions [35,36] . The second significant pathway is the axonal guidance signaling 
pathway (P = 2.54 × 10−4, adjusted P = 0.012), which is critical for neural development. 
The mRNA expression levels of axon guidance molecules have been found to be altered 
in some brain regions of cocaine-treated rats, which may contribute to drug abuse-
associated cognitive impairment [37,38]. Each of the two pathways remained significant 
when we performed pathway analysis, using the same P-value cutoff value to select top 
SNPs, based on the L-BRAT results generated under the independence and AR(1) 
working correlation, respectively. In contrast, only the opioid signaling pathway was 
significant based on the results from the GEE analysis using the independent working 
correlation, and only the axonal guidance signaling pathway was significant based on the 
RGMMAT results, whereas neither of them remained significant based on the GMMAT 
results and that from the GEE analysis with an AR(1) working correlation. These results 
demonstrate that L-BRAT provides more informative association results to help identify 
biological relevant pathways. 
Lastly, we performed an enrichment analysis to see whether the top SNPs in our 
analysis are more likely to regulate brain gene expression. We considered the local 
expression quantitative trait loci (cis-eQTLs) reported in 13 human brain regions from the 
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Genotype-Tissue Expression (GTEx) project [39,40], including amygdala, anterior 
cingulate cortex, caudate, cerebellar hemisphere, cerebellum, cortex, frontal cortex, 
hippocampus, hypothalamus, nucleus accumbens, putamen, spinal cord, and substantia 
nigra. Fisher’s exact test was used to assess the enrichment of eQTLs (FDR < 0.05) in 
the top 2,778 SNPs for which at least one of the longitudinal tests had a P-value < 10−4 
in the VACS sample. Among the 13 brain regions, amygdala is the only region in which 
eQTLs showed significant enrichment in our top SNP list (odds ratio = 2.06, P =
3.0 × 10−5). 
Replication of top findings 
Nevertheless, we performed pathway analysis using the SNP summary statistics of 
Yale-Penn to replicate the two pathways identified in the VACS sample. Among the top 
2,778 SNPs for which at least one of the longitudinal tests had a P-value < 10−4, we 
were able to retrieve 2,602 SNP summary statistics from Yale-Penn. Pathway analysis 
was conducted on the top 84 SNPs that had a P-value < 0.05. Although none of the top 
twelve SNPs in Table 1.2 had a P-value < 0.05 in the Yale-Penn AA sample, each of the 
two pathways remained significant: the opioid signaling pathways (P = 5.67 × 10−4, 
adjusted P = 3.77 × 10−3) and the axonal guidance signaling (P = 2.89 × 10−4, 
adjusted P = 2.97 × 10−3). 
1.4.4 Computation Time 
The computational burden of the two retrospective tests, L-BRAT and RGMMAT, 
mainly comes from the eigendecomposition of the GRM in calculating the retrospective 
variance of the score functions. However, its impact on run time is minimal because the 
decomposition needs to be done only once per genome scan. When fitting the null 
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models, the GLMM-based methods require extra time to obtain the estimates of random 
effects compared to the GEE-based methods. Once the null model is obtained, the 
transformed phenotypic residual vector, 𝚪𝚪�0
1/2𝚺𝚺�0−1𝚪𝚪�0
−1/2(𝒀𝒀 − 𝝁𝝁�0), in L-BRAT and the 
phenotypic residual vector, 𝒀𝒀 − 𝝁𝝁�0, in RGMMAT, need to be calculated just once per 
genome scan. Thus, the computational cost of the variance in the retrospective tests is 
much less than that in the prospective tests. We reported some example run times for 
analysis of simulated and real data. For a simulated dataset of phenotypes at five time 
points on 2,000 individuals, the GEE-based methods took 0.9 s while the GLMM-based 
methods took 37 s to fit the null model. Overall, L-BRAT took 2.4 s and GEE took 27.7 s 
to analyze 1,000 SNPs using a single processor on an Intel Xeon 2.6 GHz CPU machine. 
In the analysis of the VACS cocaine use data, L-BRAT and GEE took 1 s while 
RGMMAT and GMMAT took 2.5 min to fit the null model. Overall, L-BRAT, 
RGMMAT, GEE, and GMMAT took 0.8 hr, 0.7 hr, 24.8 hr, and 26.2 hr, respectively, to 
analyze a total of 10,215,072 genome-wide SNPs on Intel Xeon 2.6 GHz CPU computing 
clusters with 22 nodes. These results demonstrate that L-BRAT and RGMMAT are 
computationally feasible for large-scale whole-genome association studies. 
 
1.5 Discussion 
Longitudinal data can be used in GWAS to improve power for identification of 
genetic variants and environmental factors that influence complex traits over time. In this 
study, we have developed L-BRAT, a retrospective association testing method for 
longitudinal binary outcomes. L-BRAT is based on GEE, thus it requires assumptions on 
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the mean but not the full distribution of the outcome. Correct specification of the 
covariance of repeated measurements within each individual is not required, instead, a 
working covariance matrix is assumed. The significance of the L-BRAT association test 
is assessed retrospectively by considering the conditional distribution of the genotype at 
the variant of interest, given phenotype and covariate information, under the null 
hypothesis of no association. Features of L-BRAT include the following: (1) it is 
computationally feasible for genetic studies with millions of variants, (2) it allows both 
static and time-varying covariates to be included in the analysis, (3) it allows different 
individuals to have measurements at different time points, and (4) it has correct type I 
error in the presence of ascertainment and trait model misspecification. For comparison, 
we also propose a retrospective, logistic mixed model-based association test, RGMMAT, 
which requires specification of the full distribution of the outcome. Random effects are 
used to model dependence among observations for an individual. Like L-BRAT, 
RGMMAT is a retrospective analysis in which genotypes are treated as random 
conditional on the phenotype and covariates. As a result, RGMMAT is also more robust 
to misspecification of the model for the phenotype distribution than GMMAT test.  
Through simulation, we demonstrated that the type I error of L-BRAT was well 
calibrated under different trait models and ascertainment schemes, whereas the type I 
error of the prospective GEE method was inflated relative to nominal levels. In the 
GLMM-based methods, GMMAT, a prospective analysis, was overly conservative, 
whereas the retrospective version, RGMMAT, was able to maintain correct type I error. 
We further demonstrated that the two retrospective tests, L-BRAT and RGMMAT, 
provided higher power to detect association than the prospective GEE and GMMAT tests 
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under all the trait models and ascertainment schemes considered in the simulations. The 
choice of the working correlation matrix in L-BRAT resulted in little loss of power. We 
applied L-BRAT and RGMMAT to longitudinal association analysis of cocaine use in the 
VACS data, where we identified six novel genes that are associated with cocaine use. 
Moreover, our pathway analysis identified two significant pathways associated with 
longitudinal cocaine use: the opioid signaling pathway and the axonal guidance signaling 
pathway. We were able to replicate both pathways in a cocaine dependence case-control 
GWAS from the Yale-Penn study. Lastly, we illustrated that the top SNPs identified by 
our methods are more likely to be the amygdala eQTLs in the GTEx data. The amygdala 
plays an important role in the processing of memory, decision-making, and emotional 
responses, and contributes to drug craving that leads to addiction and relapse  [41,42]. 
These findings verify that L-BRAT is able to detect important loci in a genome scan and 
to provide novel insights into the disease mechanism in relevant tissues. Both simulation 
studies and the real data analysis suggest that, in general, L-BRAT is a more robust and at 
the same time, computationally more efficient test than RGMMAT.  
Although both L-BRAT and RGMMAT are proposed for population samples, they 
can be easily extended to related samples in family data for whom the pedigree structure 
is known. Use the similar strategy of CERAMIC, which extends the CARAT to related 
samples,  it would allow us to incorporate the partially missing data to enhance power. To 
extend L-BRAT to family design, we could include the kinship matrix into the correlation 
structure and also modify the genotypic model to incorporate the possibility that genotype 
being related to covariates. Also, we should consider a more robust variance estimator 
that incorporating kinship matrix into estimation.  
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The L-BRAT and RGMMAT methods are designed for single-variant association 
analysis of longitudinally measured binary outcomes. However, single-variant association 
tests in general have limited power to detect association for low-frequency or rare 
variants in sequencing studies. We have previously developed longitudinal burden test 
and sequence kernel association test, LBT and LSKAT, to analyze rare variants with 
longitudinal quantitative phenotypes [19]. Both tests are based on a prospective approach. 
To extend L-BRAT and RGMMAT to rare variant analysis with longitudinal binary data, 
we could consider either a linear statistic or a quadratic statistic that combines the 
retrospective score test at each variant in a gene region. In addition, the genetic effect in 
L-BRAT and RGMMAT is assumed to be constant. We could consider an extension to 
allow for time-varying genetic effect so that the fluctuation of genetic contributions to the 







Variant-set Retrospective Association Tests 
for Longitudinal Traits 
2.1 Abstract 
Longitudinal repeated measures have been increasingly used in genome-wide 
association studies. The repeated measures provide an opportunity to study the temporal 
development of traits and also increase the statistical power in association tests. Most of 
the existing variants-set association tests are based on a population model in which 
ascertainment sampling is ignored. Prospective inference with longitudinal traits and rare 
variants can have inflated type I error when the trait model is misspecified. Here, we 
propose LSRAT (Longitudinal variant-Set Retrospective Association Tests) and 
RSMMAT (Retrospective variant-Set Mixed Model Association Tests), two groups of 
retrospective variant-set tests that are constructed based on the genotype model given the 
phenotype and covariates. RSMMAT can be viewed as a retrospective version of the 
recently proposed variant-set mixed model association tests (SMMAT) and the LSRAT 
tests are derived under the generalized estimation equation framework. These two 
retrospective tests are robust against trait model misspecification and are computationally 
more efficient than existing prospective approaches. Simulation studies showed that our 
proposed tests are robust to the trait model misspecification and gain power compared to 
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SMMAT. We illustrated our method in the Veterans Aging Cohort Study to evaluate the 
association of repeated measures of alcohol use disorder with rare variants.  
 
2.2 Introduction 
Longitudinally measured phenotypes where each individual has multiple follow-ups 
over the time are more available in genome-wide association studies (GWAS). With the 
emergence of electronic health record (EHR) in large long-term studies such as UK 
Biobank and Million Veteran Program, longitudinal measures are vastly being introduced 
to genomic studies and GWAS. Compared to analysis based on single-time-point 
measures or traits values averaged over time, longitudinal measures make full use of 
phenotype information which renders more powerful genetic association tests. Moreover, 
analyzing longitudinal measures enables the incorporation and adjusting for time-varying 
covariates into the model. It also delivers the opportunity to study temporal development 
of complex traits. Because of these merits, an increasing number of studies have 
developed association tests using longitudinally measured phenotypes in GWAS 
[3,4,14,43–45]. However, most studies have only focused on single variant tests.  
Regardless of the extensive discovery of the genetic common variants associated with 
complex traits, the identified genetic variants explain only a fraction of total heritability 
which is often termed “missing heritability”. Although many possible explanations have 
been proposed, one of the most widely accepted is that the additional heritability can be 
found by studying rare variants which have the minor allele frequency (MAF) of less than 
5% [46]. However, single variant tests for rare variants are underpowered due to the 
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extremely low MAF. In this regard, many various variant-set association tests have been 
developed to aggregate multiple rare variants within a region, for example, within a gene 
or a biological pathway, to increase the detection power. Among such tests, the most two 
popular approaches are burden tests and the Sequence Kernel Association Test 
(SKAT)[47]. Burden tests consider a weighted sum of multiple genetic variants into a 
single score and are powerful when the effects of those variants in a group are 
homogeneity in direction and magnitude [48]. However, when the genomic region of 
interest contains signal of both directions (e.g., both risk and protective effects), burden 
tests may lose power. By contrast, SKAT evaluates the variance of the genetic effects of 
a group of genetic variants by adopting a statistic of quadratic form. It is more robust to 
regions where variants’ effects are in opposite directions [49] and allows different 
directions and magnitudes of signals. There are several omnibus tests that unify both the 
burden and SKAT tests and borrow strength from both approaches, for example, the 
SKAT-O[47], MiST[50], aSPU[51], SMMAT-E[52], and ACAT-O [53]. Recently, an 
aggregated Cauchy association test (ACAT) has been proposed which efficiently 
combines Cauchy transformed p-values. The set-based ACAT (ACAT-V) which 
combines variant-level p-values has been shown to have strong power when the genetic 
association signal is sparse; and the omnibus ACAT (ACAT-O) which combines multiple 
set-based tests provides another strategy to combine SKAT and burden statistics. 
However, all these variant-set association tests were developed for single-time-point 
measures and are not directly applicable to longitudinal repeated measures. Thus, there is 
a pressing need to develop powerful and efficient variant-set tests for rare variants in 
longitudinal GWA studies. 
47 
 
There are some attempts to fill this need. For example, Wang et al. extended the 
burden and the SKAT statistics for longitudinal continuous phenotypes by introducing L-
Burden and L-SKAT[44]. The two tests were developed under the linear mixed model 
framework that takes into account interpersonal correlation. Similarly, He et al. extended 
the GEE-based SKAT test for longitudinal continuous traits[54]. However, these tests 
were derived from prospective models, and therefore rely on the correct specification of 
phenotype model to maintain correct type I errors. Yet for longitudinal dichotomous 
traits, especially for rare diseases and conditions, efficient sampling is widely used in 
which subjects are usually sampled based on their baseline measures. Prospective 
analysis in which a population-based model is used overlooks the ascertainment bias and 
may cause compromised statistical inference[10]. To overcome this limitation, several 
retrospective association methods have been proposed to analyze ascertained case-control 
studies [10,12]. Contrast to prospective analysis, retrospective approaches in which 
genotypes are treated as random conditional on phenotype and covariates are robust to 
phenotype model misspecification and ascertainment bias. Recently, we extended the 
retrospective tests to the study of longitudinal binary traits by proposing L-BRAT (GEE-
based) and RGMMAT (GLMM-based). However, both L-BRAT and RGMMAT are 
single-variant test designed for common genetic variant and thus there still lacks 
retrospective approaches for longitudinal variant-set association test.  
Here, we propose LSRAT (Longitudinal variant-Set Retrospective Association Tests) 
and RSMMAT (Retrospective variant-Set Mixed Model Association Tests), two groups 
of longitudinal retrospective variant-set tests that are constructed based on the genotype 
model given the phenotype and covariates. RSMMAT can be viewed as a retrospective 
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version of the recently proposed variant-set mixed model association tests (SMMAT) and 
the LSRAT tests are derived under the generalized estimation equation (GEE) 
framework. These tests have several advantages: (1) they are robust against trait model 
misspecification; (2) they are able to adjust both static and time-varying covariates; (3) 
they allow for related subjects and account for population structure; and (4) they are 
computationally more efficient than existing prospective approaches. Simulation studies 
showed that our proposed tests are robust to the trait model misspecification and gain 
power compared to SMMAT and GEE tests. We illustrated our method in the Veterans 




We consider the problem of association testing between a set of variants in a genetic 
region and a longitudinal trait. Suppose genotype, phenotype, and covariate data on a 
sample of 𝑛𝑛 individuals are available. The genotype data consist of genotypes at the 𝑚𝑚 
variants to be tested. The phenotype data consist of repeated measurements of a 
continuous or binary trait. The covariates are allowed to have both static variables such as 
sex and dynamic variables such as age. We let 𝑛𝑛𝑖𝑖 denote the number of phenotype 
measures on individual 𝑖𝑖 and 𝑁𝑁 = ∑ 𝑛𝑛𝑖𝑖𝑛𝑛𝑖𝑖=1  denote the total number of observations. For 
the 𝑖𝑖th individual, let 𝑌𝑌𝑖𝑖𝑖𝑖 be the trait value, continuous or binary, and 𝑿𝑿𝑖𝑖𝑖𝑖 be the 𝑝𝑝-
dimensional covariate vector including an intercept, measured at time 𝑡𝑡𝑖𝑖𝑖𝑖. We define 𝒀𝒀 =
(𝑌𝑌1,1, … ,𝑌𝑌1,𝑛𝑛1 , … ,𝑌𝑌𝑛𝑛,1, … ,𝑌𝑌𝑛𝑛,𝑛𝑛𝑛𝑛)
𝑇𝑇, the trait vector of length 𝑁𝑁, and 𝑿𝑿 =
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(𝑋𝑋1,1, … ,𝑋𝑋1,𝑛𝑛1 , … ,𝑋𝑋𝑛𝑛,1, … ,𝑋𝑋𝑛𝑛,𝑛𝑛𝑛𝑛)
𝑇𝑇, the 𝑁𝑁 × 𝑝𝑝 covariate matrix. Let 𝑮𝑮 denote the 
𝑛𝑛 × 𝑚𝑚 matrix of genotypes, where 𝐺𝐺𝑖𝑖𝑖𝑖 = 0, 1, or 2 is the number of minor alleles of 
individual 𝑖𝑖 at the 𝑘𝑘th variant. Here the genotype matrix 𝑮𝑮 is indexed by individual rather 
than by measurement. In order to match the dimensions of 𝒀𝒀 and 𝑿𝑿, we consider a 
vertically expanded genotype matrix 𝑩𝑩𝑮𝑮 that maps the genotype data 𝑮𝑮 from the 
individual level to the measurement level, where 𝑩𝑩 is defined as an 𝑁𝑁 × 𝑛𝑛 design matrix 
representing the measurement clustering structure, and its (𝑙𝑙, 𝑖𝑖)th entry 𝐵𝐵𝑙𝑙𝑖𝑖 is an indicator 
that the 𝑙𝑙th entry of 𝒀𝒀 belongs to the measurements on individual 𝑖𝑖. 
In what follows, we introduce three groups of association testing methods for 
longitudinal traits: (1) GEE-based prospective association tests; (2) LSRAT 
(Longitudinal variant-Set Retrospective Association Tests); and (3) RSMMAT 
(Retrospective variant-Set Mixed Model Association Tests). Like the SMMAT tests [52], 
the GEE-based association tests are prospective analyses in which 𝒀𝒀 is treated as random 
conditional on 𝑮𝑮 and 𝑿𝑿, whereas LSRAT and RSMMAT are retrospective analyses in 
which 𝑮𝑮 is treated as random conditional on 𝒀𝒀 and 𝑿𝑿. 
2.3.1 Generalized Estimating Equations (GEEs) 
In the GEE-based analysis, we model the mean of the phenotype distribution, given 
the genotypes and covariates, as follows 
𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � 𝑮𝑮,𝑿𝑿� = 𝜇𝜇𝑖𝑖𝑖𝑖 ,   𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖� = 𝑿𝑿𝑖𝑖𝑖𝑖𝑇𝑇 𝜶𝜶 + 𝑮𝑮𝑖𝑖𝑇𝑇𝜷𝜷,   𝑖𝑖 = 1, … ,𝑛𝑛;  𝑗𝑗 = 1, … ,𝑛𝑛𝑖𝑖 ,           (1) 
where 𝜶𝜶 is an unknown 𝑝𝑝-dimentional vector of covariate effects, 𝜷𝜷 is an unknown 
𝑚𝑚-dimensional vector of genotype effects, and 𝑔𝑔( ) is a link function, for example, 
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𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖� = 𝜇𝜇𝑖𝑖𝑖𝑖 for continuous phenotypes, and 𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖� = logit(𝜇𝜇𝑖𝑖𝑖𝑖) for binary phenotypes. 
The covariance matrix of 𝒀𝒀, denoted by 𝛀𝛀, is specified as 
Var(𝒀𝒀 | 𝑮𝑮,𝑿𝑿) = 𝛀𝛀 = 𝜙𝜙𝚪𝚪1/2𝚺𝚺𝚪𝚪1/2, 
where 𝚪𝚪 = diag�𝑣𝑣�𝜇𝜇1,1�, … , 𝑣𝑣�𝜇𝜇1,𝑛𝑛1�, … , 𝑣𝑣�𝜇𝜇𝑛𝑛,1�, … , 𝑣𝑣�𝜇𝜇𝑛𝑛,𝑛𝑛𝑛𝑛�� is an 𝑁𝑁-dimentional 
diagonal matrix, 𝑣𝑣( ) is the variance function, with 𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖� = 1 for continuous traits and 
𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖� = 𝜇𝜇𝑖𝑖𝑖𝑖�1 − 𝜇𝜇𝑖𝑖𝑖𝑖� for binary traits, 𝚺𝚺 is an 𝑁𝑁 × 𝑁𝑁 working correlation matrix which 
may depend on some parameter 𝛿𝛿, and 𝜙𝜙 > 0 is a dispersion parameter, with 𝜙𝜙 = 𝜎𝜎2 for 
continuous phenotypes and 𝜙𝜙 = 1 for binary phenotypes. The working correlation matrix 
𝚺𝚺 is allowed to be misspecified. In Model (1), the genotype effects 𝜷𝜷 are assumed to 
follow a distribution with mean 𝑾𝑾𝟏𝟏𝑚𝑚𝛽𝛽0 and covariance 𝜏𝜏𝑾𝑾𝑾𝑾, where 𝑾𝑾 =
diag(𝑤𝑤1, … ,𝑤𝑤𝑚𝑚) is a fixed, prespecified 𝑚𝑚-dimentional diagonal weight matrix, 𝟏𝟏𝑚𝑚 is an 
𝑚𝑚-vector of 1’s, and 𝜏𝜏 is the variance component of genotype effects. The weights 
𝑤𝑤1, … ,𝑤𝑤𝑚𝑚 specify how the genotype effects depend on particular features of the variants. 
Various weighting schemes are available, such as uniform weighting, weighting based on 
some function of the minor allele frequency (MAF) of the variants [49,55], and function 
or annotation-based weighting. 







where 𝚫𝚫 = diag�𝑢𝑢�𝜇𝜇1,1�, … ,𝑢𝑢�𝜇𝜇1,𝑛𝑛1�, … ,𝑢𝑢�𝜇𝜇𝑛𝑛,1�, … ,𝑢𝑢�𝜇𝜇𝑛𝑛,𝑛𝑛𝑛𝑛�� is an 𝑁𝑁-dimentional 
diagonal matrix and 𝑢𝑢( ) is the first derivative of 𝑔𝑔−1( ). To detect association between 
51 
 
the trait and the genetic region of interest, we test 𝐻𝐻0:𝜷𝜷 = 𝟎𝟎 vs. 𝐻𝐻1:𝜷𝜷 ≠ 𝟎𝟎. The score 
function for the genotype effects 𝜷𝜷 under 𝐻𝐻0 can be written as 
𝑼𝑼0(𝜷𝜷) = 𝑼𝑼(𝜷𝜷)|𝜶𝜶�0,𝟎𝟎,𝛿𝛿�0 = (𝑩𝑩𝑮𝑮)
𝑇𝑇𝚫𝚫�0𝛀𝛀�0−1(𝒀𝒀 − 𝝁𝝁�0). 
Here 𝝁𝝁�0, 𝚫𝚫�0 and 𝛀𝛀�0 are 𝝁𝝁, 𝚫𝚫 and 𝛀𝛀 evaluated at (𝜶𝜶,𝜷𝜷, 𝛿𝛿) = �𝜶𝜶�0,𝟎𝟎, ?̂?𝛿0�, where 𝜶𝜶�0 and ?̂?𝛿0 
are the null estimates of 𝜶𝜶 and 𝛿𝛿 under the constraint 𝜷𝜷 = 𝟎𝟎, which can be computed 
iteratively between a Fisher scoring algorithm for 𝜶𝜶 and the method of moments for 𝛿𝛿 
until convergence. 
Hypothesis Testing: GEE-B, GEE-S, GEE-O, GEE-E, GEE-C, and GEE-A 
In the GEE model of Eq. (1), our primary interest is to test the genotype effects 
𝐻𝐻0:𝜷𝜷 = 𝟎𝟎, which is equivalent to test the null hypothesis 𝐻𝐻0:𝛽𝛽0 = 0 and 𝜏𝜏 = 0. If we 
assume 𝜏𝜏 = 0 and test the null hypothesis 𝐻𝐻0:𝛽𝛽0 = 0, the GEE-based burden test GEE-B 
has the form 
𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵 = (𝒀𝒀 − 𝝁𝝁�0)𝑇𝑇𝛀𝛀�0−1𝚫𝚫�0𝑩𝑩𝑮𝑮𝑾𝑾𝟏𝟏𝑚𝑚𝟏𝟏𝑚𝑚𝑇𝑇 𝑾𝑾𝑮𝑮𝑇𝑇𝑩𝑩𝑇𝑇𝚫𝚫�0𝛀𝛀�0−1(𝒀𝒀 − 𝝁𝝁�0).                (2) 
Under the null hypothesis, the statistic 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵 is asymptotically distributed as 𝜑𝜑𝐵𝐵𝜒𝜒12, 
where 𝜒𝜒12 is a chi-squared distribution with 1 df, the scalar 𝜑𝜑𝐵𝐵 = 𝟏𝟏𝑚𝑚𝑇𝑇 𝑾𝑾𝑮𝑮𝑇𝑇𝑩𝑩𝑇𝑇𝑸𝑸𝑩𝑩𝑮𝑮𝑾𝑾𝟏𝟏𝑚𝑚 
and 𝑸𝑸 = 𝚲𝚲 − 𝚲𝚲𝑿𝑿(𝑿𝑿𝑇𝑇𝚲𝚲𝑿𝑿)−1𝑿𝑿𝑇𝑇𝚲𝚲, where 𝚲𝚲 = 𝚫𝚫�0𝛀𝛀�0−1Cov� (𝒀𝒀)𝛀𝛀�0−1𝚫𝚫�0 and the sample 
covariance of 𝒀𝒀, Cov� (𝒀𝒀), is estimated by (𝒀𝒀 − 𝝁𝝁�0)(𝒀𝒀 − 𝝁𝝁�0)𝑇𝑇. 
If we assume 𝛽𝛽0 = 0 and test 𝐻𝐻0: 𝜏𝜏 = 0, the GEE-based variance component SKAT 
test GEE-S has the form 




Under the null hypothesis, 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑆𝑆 asymptotically follows ∑ 𝜑𝜑𝑆𝑆𝑘𝑘𝜒𝜒1,𝑘𝑘
2𝑚𝑚
𝑘𝑘=1 , where 𝜒𝜒1,𝑘𝑘2  are 
independent chi-squared distributions with 1 df, and 𝜑𝜑𝑆𝑆𝑘𝑘 are the eigenvalues of the matrix 
𝑾𝑾𝑮𝑮𝑇𝑇𝑩𝑩𝑇𝑇𝑸𝑸𝑩𝑩𝑮𝑮𝑾𝑾. 
Like SKAT-O, we can combine the SKAT and burden tests by considering 
𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑂𝑂 = 𝜋𝜋𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵 + (1 − 𝜋𝜋)𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑆𝑆. 
We can see that 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑂𝑂 reduces to the GEE burden test when 𝜋𝜋 = 1 and to the GEE 
SKAT test when 𝜋𝜋 = 0. An optimal 𝜋𝜋 can be chosen from the data by minimizing the p 
value of 𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝑂𝑂, following a similar approach to the SKAT-O method[47]. 
An alternative joint test, similar to MiST [50] and SMMAT-E [52] that were designed 
under the mixed effects models, for testing 𝐻𝐻0:𝛽𝛽0 = 0 and 𝜏𝜏 = 0 can be constructed as 
two independent tests: (1) a test for 𝐻𝐻0:𝛽𝛽0 = 0 under the constraint 𝜏𝜏 = 0, and (2) a test 
for 𝐻𝐻0: 𝜏𝜏 = 0 without any constraint on 𝛽𝛽0. The first test is the GEE burden statistic 
𝑇𝑇𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵, and the second test 𝑇𝑇𝜏𝜏 can be constructed as 
𝑇𝑇𝜏𝜏 = (𝒀𝒀 − 𝝁𝝁�)𝑇𝑇𝛀𝛀�−1𝚫𝚫�𝑩𝑩𝑮𝑮𝑾𝑾𝑾𝑾𝑮𝑮𝑇𝑇𝑩𝑩𝑇𝑇𝚫𝚫�𝛀𝛀�−1(𝒀𝒀 − 𝝁𝝁�), 
where 𝝁𝝁�, 𝚫𝚫� and 𝛀𝛀�  are 𝝁𝝁, 𝚫𝚫 and 𝛀𝛀 evaluated at (𝜶𝜶,𝜷𝜷, 𝛿𝛿) = �𝜶𝜶�,𝑾𝑾𝟏𝟏𝑚𝑚𝛽𝛽�0, 𝛿𝛿�. Here 𝜶𝜶�, 𝛽𝛽�0 
and 𝛿𝛿 are the estimates of 𝜶𝜶, 𝛽𝛽0 and 𝛿𝛿 under a burden-type of mean model 
𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � 𝑮𝑮,𝑿𝑿� = 𝜇𝜇𝑖𝑖𝑖𝑖 ,   𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖� = 𝑿𝑿𝑖𝑖𝑖𝑖𝑇𝑇 𝜶𝜶 + 𝑮𝑮𝑖𝑖𝑇𝑇𝑾𝑾𝟏𝟏𝑚𝑚𝛽𝛽0,   𝑖𝑖 = 1, … ,𝑛𝑛;  𝑗𝑗 = 1, … ,𝑛𝑛𝑖𝑖 .      (4) 
We can show that 
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where 𝑷𝑷� = 𝚫𝚫�0𝛀𝛀�0−1𝚫𝚫�0 − 𝚫𝚫�0𝛀𝛀�0−1𝚫𝚫�0𝑿𝑿�𝑿𝑿𝑇𝑇𝚫𝚫�0𝛀𝛀�0−1𝚫𝚫�0𝑿𝑿�
−1𝑿𝑿𝑇𝑇𝚫𝚫�0𝛀𝛀�0−1𝚫𝚫�0. 
Some assumptions: Since the true value of 𝛽𝛽0 small, we assume including the 
genetic burden score in Eq. (4) doesn’t dramatically change the variance function matrix 
𝚫𝚫 and 𝛀𝛀. Independence holds when the working correlation matches the true correlation. 
Alternatively, one can apply ACAT approach to combine P values of individual tests. 





where 𝑝𝑝𝑘𝑘 is the P-value of score test of the kth genetic variants; 𝑤𝑤𝑘𝑘′ =
𝑤𝑤𝑘𝑘�𝑀𝑀𝑀𝑀𝐹𝐹𝑘𝑘(1 −𝑀𝑀𝑀𝑀𝐹𝐹𝑘𝑘) specifies the weight for the P-value which depends on the minor 
allele frequency of genetic variant; 𝑓𝑓(𝑥𝑥) =  𝑡𝑡𝑡𝑡𝑛𝑛{(0.5 − 𝑥𝑥)𝜋𝜋} performs Cauchy 
transformation on each of the P-values. And the omnibus ACAT test can be used to 




[𝑓𝑓(𝑝𝑝𝐺𝐺𝐺𝐺𝐺𝐺−𝐵𝐵) + 𝑓𝑓(𝑝𝑝𝐺𝐺𝐺𝐺𝐺𝐺−𝑆𝑆) + 𝑓𝑓(𝑝𝑝𝐺𝐺𝐺𝐺𝐺𝐺−𝐶𝐶)] 




In contrast to SMMAT [52] and the GEE-based association tests which are 
prospective analyses based on the phenotype given the genotypes and covariates, LSRAT 
and RSMMAT are retrospective analyses based on the genotypes given the phenotype 
and covariates. The advantage of the retrospective approach is that the inference is robust 
to misspecification of the phenotype model, i.e., the type I error of the association tests is 
still properly controlled given correct specification of the null conditional mean and 
variance of the genotype data, but not the phenotype model. Since LSRAT and 
RSMMAT have very similar forms, for clarity, we first present the retrospective model 
and the test statistics for LSRAT, and then briefly describe the RSMMAT statistics and 
emphasize the differences between the two retrospective analyses. 
 
2.3.2 LSRAT Model and test statistics 
In LSRAT, we specify a retrospective mean model of the genotype 
𝐸𝐸(𝑮𝑮𝑘𝑘 |𝒀𝒀,𝑿𝑿) = 2𝑝𝑝𝑘𝑘𝟏𝟏𝑛𝑛 + 𝛾𝛾𝑘𝑘𝚽𝚽𝑨𝑨,   𝑘𝑘 = 1, … ,𝑚𝑚,                                  (5) 
where 𝑮𝑮𝑘𝑘 is the genotype vector at the 𝑘𝑘th variant, 𝑝𝑝𝑘𝑘 is its MAF which is treated as an 
unknown nuisance parameter, 𝛾𝛾𝑘𝑘 is an unknown parameter of interest representing the 
strength and direction of association between the phenotype and the 𝑘𝑘th variant, 𝟏𝟏𝑛𝑛 is an 
𝑛𝑛-vector of 1’s, 𝚽𝚽 is an 𝑛𝑛 × 𝑛𝑛 genetic relationship matrix (GRM) representing the overall 
genetic similarity between individuals due to population structure, and 𝑨𝑨 is an individual-
level transformed phenotypic residual vector, where we let 𝑨𝑨 = 𝑩𝑩𝑇𝑇𝚫𝚫�0𝛀𝛀�0−1(𝒀𝒀 − 𝝁𝝁�0), 
obtained from the null GEE model 𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖� = 𝑿𝑿𝑖𝑖𝑖𝑖𝑇𝑇 𝜶𝜶, for 𝑖𝑖 = 1, … ,𝑛𝑛;  𝑗𝑗 = 1, … ,𝑛𝑛𝑖𝑖. If we let 
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𝑮𝑮� = vec(𝑮𝑮) = (𝑮𝑮1𝑇𝑇 , … ,𝑮𝑮𝑚𝑚𝑇𝑇 )𝑇𝑇 be an 𝑛𝑛𝑚𝑚-dimentional vector denoting the vectorization of 
the genotype matrix 𝑮𝑮, Model (5) can be equivalently written as 
𝐸𝐸�𝑮𝑮� �𝒀𝒀,𝑿𝑿� = 2𝒑𝒑⊗ 𝟏𝟏𝑛𝑛 + 𝜸𝜸⊗𝚽𝚽𝑨𝑨,                                         (6) 
where 𝒑𝒑 = (𝑝𝑝1, … , 𝑝𝑝𝑚𝑚)𝑇𝑇 is a vector of the MAFs of the 𝑚𝑚 genetic variants, 𝜸𝜸 =
(𝛾𝛾1, … , 𝛾𝛾𝑚𝑚)𝑇𝑇 is an unknown vector of association parameters of interest, and ⊗ is 
Kronecker product. 
To form LSRAT, we require the null conditional covariance matrix of 𝑮𝑮�, which can 
be specified as 
Var0�𝑮𝑮� �𝒀𝒀,𝑿𝑿� = 𝚺𝚺𝐺𝐺 ⊗𝚽𝚽,                                               (7) 
where 𝚺𝚺𝐺𝐺 = 𝑫𝑫1/2𝑹𝑹𝑫𝑫1/2 is an 𝑚𝑚 × 𝑚𝑚 covariance matrix of the variants. Here 𝑫𝑫 =
diag(𝜎𝜎12, … ,𝜎𝜎𝑚𝑚2 ) is the marginal variance of the 𝑚𝑚 genetic variants, and 𝑹𝑹 is the 
correlation matrix that captures the linkage disequilibrium (LD) structure. In Model (6), 
the genotype-phenotype association parameters 𝜸𝜸 are assumed to follow a distribution 
with mean 𝑽𝑽𝟏𝟏𝑚𝑚𝛾𝛾0 and covariance 𝜃𝜃𝑽𝑽𝑽𝑽𝑇𝑇, where 𝑽𝑽 is a prespecified 𝑚𝑚 × 𝑚𝑚 weight matrix 
and 𝜃𝜃 is the variance component of the association parameters. Note that the weight 
matrix 𝑽𝑽 in the retrospective model of Eq. (6) plays a similar role as the weight matrix 𝑾𝑾 
in the prospective GEE model of Eq. (1) that is allowed to depend on features of the 
variants. However, we do not require 𝑽𝑽 to be a diagonal or symmetric matrix. In fact, the 
connection between 𝜸𝜸 of Eq. (6) and 𝜷𝜷 of Eq. (1) is that 𝜸𝜸 = 𝚺𝚺𝐺𝐺𝜷𝜷 when 𝜷𝜷 tends to zero. 
Therefore, one choice for the weight matrix 𝑽𝑽 in the retrospective model (6) is that 𝑽𝑽 =
𝚺𝚺𝐺𝐺𝑾𝑾. Then, the quasi-likelihood score function for 𝜸𝜸 is given by (see Supplementary 
Materials S 2.1) 
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𝑼𝑼(𝜸𝜸) = 𝚺𝚺𝐺𝐺−1𝑮𝑮𝑇𝑇𝑨𝑨 − (𝑨𝑨𝑇𝑇𝚽𝚽𝑨𝑨)𝚺𝚺𝐺𝐺−1𝜸𝜸. 
 
Hypothesis Testing: LSRAT-B, LSRAT-S, LSRAT-O, LSRAT-E, LSRAT-C, and 
LSRAT-A 
To detect association between the trait and a genetic region of interest, we test 
𝐻𝐻0:𝜸𝜸 = 𝟎𝟎 vs. 𝐻𝐻1:𝜸𝜸 ≠ 𝟎𝟎 in the retrospective model for 𝑮𝑮 conditional on 𝒀𝒀 and 𝑿𝑿 given in 
Eq. (6), which is equivalent to test the null hypothesis 𝐻𝐻0: 𝛾𝛾0 = 0 and 𝜃𝜃 = 0. If we 
assume 𝜃𝜃 = 0 and test 𝐻𝐻0: 𝛾𝛾0 = 0, the LSRAT burden statistic LSRAT-B can be 
constructed as 
𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝐵𝐵 = 𝑼𝑼0𝑇𝑇(𝜸𝜸)𝑽𝑽𝟏𝟏𝑚𝑚𝟏𝟏𝑚𝑚𝑇𝑇 𝑽𝑽𝑇𝑇𝑼𝑼0(𝜸𝜸) = 𝑨𝑨𝑇𝑇𝑮𝑮𝚺𝚺�𝐺𝐺−1𝑽𝑽𝟏𝟏𝑚𝑚𝟏𝟏𝑚𝑚𝑇𝑇 𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1𝑮𝑮𝑇𝑇𝑨𝑨,            (8) 
where 𝑼𝑼0(𝜸𝜸) = 𝑼𝑼(𝜸𝜸)|𝜸𝜸=𝟎𝟎 = 𝚺𝚺�𝐺𝐺−1𝑮𝑮𝑇𝑇𝑨𝑨. Under the null model, the covariance of 𝑮𝑮𝑇𝑇𝑨𝑨 is 
Cov(𝑮𝑮𝑇𝑇𝑨𝑨) = (𝑨𝑨𝑇𝑇𝚽𝚽𝑨𝑨)𝚺𝚺𝐺𝐺 (see Supplementary Materials S2.2 for details). Then, the 
statistic 𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝐵𝐵 asymptotically follows 𝜆𝜆𝐵𝐵𝜒𝜒12, where the scalar 𝜆𝜆𝐵𝐵 =
(𝑨𝑨𝑇𝑇𝚽𝚽𝑨𝑨)𝟏𝟏𝑚𝑚𝑇𝑇 𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1𝑽𝑽𝟏𝟏𝑚𝑚 and 𝜒𝜒12 is a chi-squared distribution with 1 df. 
If we assume 𝛾𝛾0 = 0 and test 𝐻𝐻0:𝜃𝜃 = 0, the LSRAT variance component SKAT 
statistic LSRAT-S can be constructed as 
𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝑆𝑆 = 𝑼𝑼0𝑇𝑇(𝜸𝜸)𝑽𝑽𝑽𝑽𝑇𝑇𝑼𝑼0(𝜸𝜸) = 𝑨𝑨𝑇𝑇𝑮𝑮𝚺𝚺�𝐺𝐺−1𝑽𝑽𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1𝑮𝑮𝑇𝑇𝑨𝑨.                        (9) 
Under the null hypothesis, 𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝑆𝑆 asymptotically follows ∑ 𝜆𝜆𝑆𝑆𝑘𝑘𝜒𝜒1,𝑘𝑘
2𝑚𝑚
𝑘𝑘=1 , where 𝜒𝜒1,𝑘𝑘2  are 
independent chi-squared distributions with 1 df, and 𝜆𝜆𝑆𝑆𝑘𝑘 are the eigenvalues of the matrix 
(𝑨𝑨𝑇𝑇𝚽𝚽𝑨𝑨)𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1𝑽𝑽. 
The SKAT-O type of test for LSRAT can be formulated as a weighted average of the 
LSRAT-B and LSRAT-S statistics, given by 
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𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝑂𝑂 = 𝜋𝜋𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝐵𝐵 + (1 − 𝜋𝜋)𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝑆𝑆. 
An optimal 𝜋𝜋 is obtained through a grid search by minimizing the p value of 𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝑂𝑂. 
Analogous to the GEE-E and SMMAT-E tests in which two independent tests were 
constructed, we can modify the quasi-likelihood score statistics to perform a joint test of 
the null hypothesis 𝐻𝐻0: 𝛾𝛾0 = 0 and 𝜃𝜃 = 0. Specifically, we first test 𝐻𝐻0: 𝛾𝛾0 = 0 under the 
constraint 𝜃𝜃 = 0, which is the LSRAT burden statistic 𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝐵𝐵, and then test 𝐻𝐻0:𝜃𝜃 = 0 
without any constraint on 𝛾𝛾0. The second variance component test can be constructed 
from the null retrospective burden model 
𝐸𝐸�𝑮𝑮� �𝒀𝒀,𝑿𝑿� = 2𝒑𝒑⊗ 𝟏𝟏𝑛𝑛 + 𝑽𝑽𝟏𝟏𝑚𝑚𝛾𝛾0 ⊗𝚽𝚽𝑨𝑨.                                     (10) 
If we assume the mean of association effects 𝛾𝛾0 is small and including the second 
term in Eq. (10) does not change the conditional covariance of 𝑮𝑮�, we obtain the estimate 
of 𝛾𝛾0, denoted by 𝛾𝛾�0, by solving the quasi-likelihood score equation 






Then, the quasi-likelihood score function for 𝜸𝜸 under Model (9) is 
𝑼𝑼𝐵𝐵(𝜸𝜸) = 𝑼𝑼(𝜸𝜸)|𝛾𝛾�0 = 𝚺𝚺�𝐺𝐺
−1𝑮𝑮𝑇𝑇𝑨𝑨 − (𝑨𝑨𝑇𝑇𝚽𝚽𝑨𝑨)𝚺𝚺�𝐺𝐺−1𝑽𝑽𝟏𝟏𝑚𝑚𝛾𝛾�0
= �𝚺𝚺�𝐺𝐺−1 − 𝚺𝚺�𝐺𝐺−1𝑽𝑽𝟏𝟏𝑚𝑚�𝟏𝟏𝑚𝑚𝑇𝑇 𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1𝑽𝑽𝟏𝟏𝑚𝑚�
−1𝟏𝟏𝑚𝑚𝑇𝑇 𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1� 𝑮𝑮𝑇𝑇𝑨𝑨 = 𝑷𝑷𝑮𝑮𝑇𝑇𝑨𝑨, 
where 𝑷𝑷 = 𝚺𝚺�𝐺𝐺−1 − 𝚺𝚺�𝐺𝐺−1𝑽𝑽𝟏𝟏𝑚𝑚�𝟏𝟏𝑚𝑚𝑇𝑇 𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1𝑽𝑽𝟏𝟏𝑚𝑚�
−1𝟏𝟏𝑚𝑚𝑇𝑇 𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1. Finally, the variance 
component statistic 𝑇𝑇𝜃𝜃 can be written as 
𝑇𝑇𝜃𝜃 = 𝑼𝑼𝐵𝐵𝑇𝑇(𝜸𝜸)𝑽𝑽𝑽𝑽𝑇𝑇𝑼𝑼𝐵𝐵(𝜸𝜸) = 𝑨𝑨𝑇𝑇𝑮𝑮𝑷𝑷𝑽𝑽𝑽𝑽𝑇𝑇𝑷𝑷𝑮𝑮𝑇𝑇𝑨𝑨. 
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Under the null hypothesis 𝐻𝐻0:𝜃𝜃 = 0, 𝑇𝑇𝜃𝜃 is asymptotically distributed as ∑ 𝜆𝜆𝜃𝜃𝑘𝑘𝜒𝜒1,𝑘𝑘
2𝑚𝑚
𝑘𝑘=1 , 
where 𝜒𝜒1,𝑘𝑘2  are independent chi-squared distributions with 1 df, and 𝜆𝜆𝜃𝜃𝑘𝑘 are the 
eigenvalues of the matrix (𝑨𝑨𝑇𝑇𝚽𝚽𝑨𝑨)𝑽𝑽𝑇𝑇𝑷𝑷𝑽𝑽. By the central limit theorem, both 𝑽𝑽𝑇𝑇𝑷𝑷𝑮𝑮𝑇𝑇𝑨𝑨 
and 𝟏𝟏𝑚𝑚𝑇𝑇 𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1𝑮𝑮𝑇𝑇𝑨𝑨 asymptotically follow normal distributions, and their covariance is 
Cov�𝑽𝑽𝑇𝑇𝑷𝑷𝑮𝑮𝑇𝑇𝑨𝑨,𝟏𝟏𝑚𝑚𝑇𝑇 𝑽𝑽𝑇𝑇𝚺𝚺�𝐺𝐺−1𝑮𝑮𝑇𝑇𝑨𝑨� = (𝑨𝑨𝑇𝑇𝚽𝚽𝑨𝑨)𝑽𝑽𝑇𝑇𝑷𝑷𝑽𝑽𝟏𝟏𝑚𝑚 = 𝟎𝟎. 
Therefore, 𝑇𝑇𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝐵𝐵 and 𝑇𝑇𝜃𝜃 are asymptotically independent. We use Fisher’s method to 
combine the p values from the two tests. 
Note that all the above four LSRAT statistics involve 𝑮𝑮𝑇𝑇𝑨𝑨, the product of the column 
vectors in the genotype matrix 𝑮𝑮 and the phenotypic residual vector 𝑨𝑨, where 𝑨𝑨 is 
obtained from the null prospective GEE model of the phenotype. As we can alternatively 
generate the phenotypic residuals based on the GLMM model of the phenotype, we 
propose in the next section a group of retrospective association testing methods using the 
phenotypic residuals obtained from the GLMM. 
The retrospective version of variant-set ACAT test and omnibus ACAT test are 









[𝑓𝑓(𝑝𝑝𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝐵𝐵) + 𝑓𝑓(𝑝𝑝𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝑆𝑆) + 𝑓𝑓(𝑝𝑝𝐿𝐿𝑆𝑆𝐿𝐿𝐴𝐴𝑇𝑇−𝐶𝐶)] 
where 𝑝𝑝𝑘𝑘𝑟𝑟 is the L-BRAT P-value on the 𝑘𝑘𝑡𝑡ℎ genetic variant (e.g., retrospective single-




2.3.3 RSMMAT Model and Test Statistics 
The SMMAT tests [52] were formulated from the GLMM 
𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖� = 𝑿𝑿𝑖𝑖𝑖𝑖𝑇𝑇 𝜶𝜶 + 𝑮𝑮𝑖𝑖𝑇𝑇𝜷𝜷 + 𝑏𝑏𝑖𝑖𝑖𝑖 ,   𝑖𝑖 = 1, … ,𝑛𝑛;  𝑗𝑗 = 1, … ,𝑛𝑛𝑖𝑖 , 
where 𝜇𝜇𝑖𝑖𝑖𝑖 = 𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � 𝑮𝑮𝒊𝒊,𝑿𝑿𝑖𝑖𝑖𝑖 , 𝑏𝑏𝑖𝑖𝑖𝑖� is the mean of a response at time 𝑡𝑡𝑖𝑖𝑖𝑖 for individual 𝑖𝑖, 
given his/her genotypes, covariates, and random effect, 𝜶𝜶 and 𝜷𝜷 are the same as defined 
in Model (1), the vector of random effects 𝒃𝒃 = (𝑏𝑏1,1, … , 𝑏𝑏1,𝑛𝑛1 , … , 𝑏𝑏𝑛𝑛,1, … , 𝑏𝑏𝑛𝑛,𝑛𝑛𝑛𝑛)
𝑇𝑇 is 
assumed that 𝒃𝒃 ∼ 𝑀𝑀𝑀𝑀𝑀𝑀(𝟎𝟎,∑ 𝜈𝜈𝑙𝑙𝐿𝐿𝑙𝑙=1 𝚽𝚽𝑙𝑙) with 𝐿𝐿 variance component parameters 𝜈𝜈𝑙𝑙, and 
correlation matrices 𝚽𝚽𝑙𝑙. Here we allow for multiple random effects to capture the 
correlation among repeated measures from longitudinal studies. 
Fitting the null GLMM model 𝑔𝑔�𝜇𝜇𝑖𝑖𝑖𝑖� = 𝑿𝑿𝑖𝑖𝑖𝑖𝑇𝑇 𝜶𝜶 + 𝑏𝑏𝑖𝑖𝑖𝑖, for 𝑖𝑖 = 1, … ,𝑛𝑛;  𝑗𝑗 = 1, … ,𝑛𝑛𝑖𝑖, we 
generate an 𝑛𝑛-dimensional vector of phenotypic residuals 𝑪𝑪 at the individual level, 
defined by 𝑪𝑪 = 𝑩𝑩𝑇𝑇(𝒀𝒀 − 𝝁𝝁�0)/𝜙𝜙�, where 𝝁𝝁�0 = 𝑔𝑔−1(𝑿𝑿𝜶𝜶�0 + 𝒃𝒃�) is a vector of fitted values, 
and 𝜙𝜙� is an estimate of the dispersion parameter 𝜙𝜙. 
Different from LSRAT, the RSMMAT model specifies that 
𝐸𝐸�𝑮𝑮� �𝒀𝒀,𝑿𝑿� = 2𝒑𝒑⊗ 𝟏𝟏𝑛𝑛 + 𝜸𝜸⊗𝚽𝚽𝑪𝑪,                                         (11) 
and the null conditional covariance matrix of 𝑮𝑮� is the same as that in Eq. (7), then the 
quasi-likelihood score function for 𝜸𝜸 is written as 𝑼𝑼(𝜸𝜸) = 𝚺𝚺𝐺𝐺−1𝑮𝑮𝑇𝑇𝑪𝑪 − (𝑪𝑪𝑇𝑇𝚽𝚽𝑪𝑪)𝚺𝚺𝐺𝐺−1𝜸𝜸. 
Finally, we construct the four RSMMAT statistics RSMMAT-B, RSMMAT-S, 
RSMMAT-O, and RSMMAT-E by replacing the phenotypic residual vector 𝑨𝑨 in the 
corresponding LSRAT tests with the GLMM-based phenotypic residual vector 𝑪𝑪; 
RSMMAT-C and RSMMAT-A by replacing the GEE score tests with GLMM ones. 
Their distributions can be similarly obtained. 
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2.3.4 Connection between Retrospective and Prospective Tests 
To assume 𝜷𝜷 has mean 𝑾𝑾𝟏𝟏𝑚𝑚𝛽𝛽0 and variance 𝜏𝜏𝑾𝑾𝑾𝑾, it would be equivalent to assume 
𝜸𝜸 has mean 𝚺𝚺𝐺𝐺𝑾𝑾𝟏𝟏𝑚𝑚𝛽𝛽0 and variance 𝜏𝜏𝚺𝚺𝐺𝐺𝑾𝑾𝑾𝑾𝚺𝚺𝐺𝐺. If we define 𝑽𝑽 = 𝚺𝚺𝐺𝐺𝑾𝑾, 𝛾𝛾0 = 𝛽𝛽0 and 
𝜃𝜃 = 𝜏𝜏, then we will have 𝑇𝑇𝐵𝐵𝑟𝑟 = 𝑇𝑇𝐵𝐵 and 𝑇𝑇𝑆𝑆𝑟𝑟 = 𝑇𝑇𝑆𝑆. Hence, we show the connection between 
retrospective burden and SKAT statistics derived from retrospective mean model and the 
original burden and SKAT test statistics. Moreover, to perform retrospective burden and 
SKAT testing, it is equivalent to evaluating the distribution of burden and SKAT score 
statistics retrospectively. 
In this section, we introduce a retrospective model, and show the connection between 
prospective and retrospective statistics. 
 
2.4 Simulation Studies 
2.4.1 Simulation of Type I Error 
We performed extensive simulations to examine the type I error of LSRAT-B, S, C, 
O, E, A and RSMMAT-B, S, C, O, E, A, and compare their empirical power with that of 
GEE and the GLMM tests. For all the simulations, we generated 10,000 chromosomes 
over a 1Mb regions using a coalescent model and mimicking the LD structure, the 
recombination rate, and the population history of the European population. We generated 
sequence data with 100 genetic variants selected from 4kb region in each set and 
1000,000 independent sets for 7,500 individuals with seven repeated measures.  
For continuous traits, in each simulation replicate, we simulated the phenotype 𝑦𝑦𝑖𝑖𝑖𝑖 for 
subject 𝑖𝑖’s 𝑗𝑗th observation under the null hypothesis without genetic effects from  
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𝑦𝑦𝑖𝑖𝑖𝑖 = 1.0 + 0.5𝑋𝑋1,𝑖𝑖 + 0.5𝑋𝑋2,𝑖𝑖𝑖𝑖 + 𝛽𝛽𝑡𝑡𝑖𝑖𝑚𝑚𝑡𝑡(𝑗𝑗 − 1) + 𝑡𝑡𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 + 𝑒𝑒𝑖𝑖𝑖𝑖 
𝑖𝑖 =  1, …𝑛𝑛; 𝑗𝑗 =  1, … 7 
where 𝑋𝑋1,𝑖𝑖 is a continuous time-varying covariate that is generated from independently 
from a standard normal distribution; 𝑋𝑋2,𝑖𝑖𝑖𝑖 is a binary time-invariant covariate with the 
probability of taking value 1 of 0.5; 𝛽𝛽𝑡𝑡𝑖𝑖𝑚𝑚𝑡𝑡 = 2.0 models time effects; 𝑡𝑡𝑖𝑖 and 𝑟𝑟𝑖𝑖𝑖𝑖 are the 
individual-level time-independent and time-dependent random effects, respectively. We 
assume 𝑡𝑡𝑖𝑖 ∼ 𝑀𝑀(0,𝜎𝜎𝑎𝑎2) and 𝑟𝑟𝑖𝑖 = (𝑟𝑟𝑖𝑖1, … 𝑟𝑟𝑖𝑖7) ∼ 𝑀𝑀𝑀𝑀𝑀𝑀(0,𝜎𝜎𝑟𝑟2𝑹𝑹), where 𝑹𝑹 is a 7 × 7 
correlation matrix specified by the AR(1) structure with a correlation coefficient 𝜓𝜓. The 
parameters for the variance components are set 𝜎𝜎𝑎𝑎2 = 𝜎𝜎𝑟𝑟2 = 𝜎𝜎𝑡𝑡2 = 0.64 and correlation 
coefficient 𝜓𝜓 = 0.7. 
For the binary traits, in each simulation replicate, we simulated the phenotype 𝑦𝑦𝑖𝑖𝑖𝑖 for 
subject 𝑖𝑖’s 𝑗𝑗th observation under the null hypothesis without genetic effects from  
logit �𝑃𝑃�𝑦𝑦𝑖𝑖𝑖𝑖 = 1�� = −2.5 + 0.5𝑋𝑋1,𝑖𝑖 + 0.5 𝑋𝑋2,𝑖𝑖𝑖𝑖 + 𝛽𝛽𝑡𝑡𝑖𝑖𝑚𝑚𝑡𝑡(𝑗𝑗 − 1) + 𝑡𝑡𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 
where 𝛽𝛽𝑡𝑡𝑖𝑖𝑚𝑚𝑡𝑡 = 0.2 represents time effects on the probability of developing the disease. 
All other parameters are the same as those in the continuous traits. We consider a 
baseline ascertainment scheme for the longitudinal dichotomous trait where 3750 case 
and 3750 control subjects were sampled according to their outcome values at baseline. 
 
2.4.2 Simulation of Empirical Power 
To assess the power performance of comparing set-based tests, we randomly selected 
causal variants within each of the genetic regions to simulate phenotypes under the 
alternatives. Specifically, we generated continuous longitudinal phenotype by 
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𝑦𝑦𝑖𝑖𝑖𝑖 = 1.0 + 0.5𝑋𝑋1,𝑖𝑖 + 0.5𝑋𝑋2,𝑖𝑖𝑖𝑖 + 𝛽𝛽𝑡𝑡𝑖𝑖𝑚𝑚𝑡𝑡(𝑗𝑗 − 1) + �𝐺𝐺𝑖𝑖𝑖𝑖𝛽𝛽𝑖𝑖
𝑠𝑠
𝑖𝑖=1
+ 𝑡𝑡𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 + 𝑒𝑒𝑖𝑖𝑖𝑖 
and dichotomous longitudinal measures by 
logit �𝑃𝑃�𝑦𝑦𝑖𝑖𝑖𝑖 = 1�� = −2.5 + 0.5𝑋𝑋1,𝑖𝑖 + 0.5 𝑋𝑋2,𝑖𝑖𝑖𝑖 +  𝛽𝛽𝑡𝑡𝑖𝑖𝑚𝑚𝑡𝑡(𝑗𝑗 − 1) + �𝐺𝐺𝑖𝑖𝑖𝑖𝛽𝛽𝑖𝑖
𝑠𝑠
𝑖𝑖=1
+ 𝑡𝑡𝑖𝑖 + 𝑟𝑟𝑖𝑖𝑖𝑖 
where 𝐺𝐺1, …𝐺𝐺𝑠𝑠 are the genotypes of randomly selected causal variants 𝛽𝛽𝑖𝑖s are the effect 
sizes for the causal variants, and the other symbols are the same as defined in the 
simulation for type I error. 
To investigate the impact of causal proportion, effect direction and sample sizes on 
the power of different tests, we vary the above factors in our power simulation studies. 
The proportion of causal variants was set to be 5%, 20% and 50% which covers cases of 
sparse and dense signals. The causal effect directions of positive/negative directions were 
set to be 50/50%, 80%/20% and all positive to represent different mixture proportions of 
protective and deleterious causal variants. The effect size (|𝛽𝛽𝑖𝑖|s) was set to be 
𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 |, such that variants with a smaller MAF have a large effect size, where the 
𝑐𝑐 depends on the causal proportion. We examined three sample size designs: 2,500, 5,000 
and 7,500. Similar to the type I error simulation, we performed baseline ascertainment for 
each of the sample size designs for the longitudinal dichotomous traits. We repeated this 
procedure 1,000 times to obtain P-values for the power estimation for each test. 
2.4.3 Simulation Results 
Table 2.1 shows the empirical type I error rates of LSRAT- B, S, C, O, E, A and 
RGMMAT- B, S, C, O, E, A and their prospective GEE tests counterparts at significance 
levels of 0.01, 0.001, and 0.0001 in the variant set analysis of continuous traits. All 
63 
 
twenty-four tests have well-controlled type I error rates at these significance levels except 
GEE-C, which has slightly conservative type I error. Table 2.2 shows the empirical type I 
error rate of the above twenty-four tests in the variant set analysis of baseline ascertained 
dichotomous traits at significance level of 0.01, 0.001, and 0.0001. All twenty-four tests 
have well-controlled type I error rates at theses significance levels for dichotomous traits. 
Table 2.1. Type I Error Estimates for Each Tests Aimed that Testing the Association Between 
Randomly Selected Genetics Regions with a Continuous Longitudinal Traits. The sample size is 7,500 
subjects with seven repeated measure and type I error rate under the basis of 106 replicates.  
  
 alpha = 0.01 alpha = 0.001 alpha = 0.0001 
  
 GEE LSRAT GEE LSRAT GEE LSRAT 
GEE-based 
Burden(B) 1.0E-02 1.0E-02 1.0E-03 1.0E-03 1.1E-04 1.0E-04 
SKAT(S) 9.0E-03 1.0E-02 9.0E-04 1.0E-03 9.0E-05 1.0E-04 
ACAT-V(C) 8.0E-03 1.0E-02 6.0E-04 1.0E-03 6.0E-05 1.1E-04 
SKAT-O(O) 1.0E-02 1.1E-02 1.1E-03 1.2E-03 1.1E-04 1.2E-04 
SMMAT-E(E) 9.0E-03 1.0E-02 9.0E-04 1.0E-03 1.0E-04 1.1E-04 
ACAT-O(A) 9.0E-03 1.1E-02 8.0E-04 1.0E-03 8.0E-05 1.1E-04 
    GLMM RSMMAT GLMM RSMMAT GLMM RSMMAT 
GLMM-based 
Burden(B) 1.0E-02 1.0E-02 1.0E-03 1.0E-03 1.0E-04 1.0E-04 
SKAT(S) 1.0E-02 1.0E-02 1.0E-03 1.0E-03 9.0E-05 9.0E-05 
ACAT-V(C) 1.0E-02 1.0E-02 1.0E-03 1.0E-03 9.0E-05 1.0E-04 
SKAT-O(O) 1.1E-02 1.1E-02 1.2E-03 1.2E-03 1.1E-04 1.1E-04 
SMMAT-E(E) 1.0E-02 1.0E-02 1.0E-03 1.0E-03 1.1E-04 1.1E-04 
ACAT-O(A) 1.1E-02 1.1E-02 1.1E-03 1.1E-03 9.0E-05 9.0E-05 
 
Table 2.2. Type I Error Estimates for Each Tests Aimed that Testing the Association Between 
Randomly Selected Genetics Regions with a Baseline Ascertained Dichotomous Longitudinal Traits. 




   
alpha = 0.01 alpha = 0.001 alpha = 0.0001 
   
GEE LSRAT GEE LSRAT GEE LSRAT 
GEE-based 
Burden(B) 
1.0E-02 1.0E-02 1.0E-03 1.0E-03 9.0E-05 1.0E-04 
SKAT(S) 
1.0E-02 1.0E-02 1.0E-03 1.0E-03 1.0E-04 1.1E-04 
ACAT-V(C) 
1.0E-02 1.0E-02 1.0E-03 1.1E-03 8.0E-05 1.2E-04 
SKAT-O(O) 
1.1E-02 1.1E-02 1.1E-03 1.2E-03 1.3E-04 1.4E-04 
SMMAT-E(E) 
1.0E-02 1.0E-02 1.0E-03 1.0E-03 1.0E-04 1.1E-04 
ACAT-O(A) 
1.0E-02 1.1E-02 1.0E-03 1.1E-03 9.0E-05 1.2E-04 
  
 GLMM RSMMAT GLMM RSMMAT GLMM RSMMAT 
GLMM-based 
Burden(B) 
1.0E-02 1.0E-02 9.0E-04 1.0E-03 7.0E-05 8.0E-05 
SKAT(S) 
1.0E-02 1.0E-02 9.0E-04 1.0E-03 8.0E-05 9.0E-05 
ACAT-V(C) 
9.0E-03 1.0E-02 9.0E-04 1.0E-03 1.1E-04 1.2E-04 
SKAT-O(O) 
1.0E-02 1.0E-02 9.0E-04 1.0E-03 9.0E-05 1.0E-04 
SMMAT-E(E) 
1.0E-02 1.1E-02 1.1E-03 1.1E-03 1.3E-04 1.4E-04 
ACAT-O(A) 
9.0E-03 1.0E-02 9.0E-04 9.0E-04 9.0E-05 1.0E-04 
 
We compare the power between LSRAT and GEE, RSMMAT and SMMAT, 
respectively under a variety of simulation conditions for both continuous and 
dichotomous traits. Figure 2.1 presents the empirical power of LSRAT- B, S, C, O, E, A 
for testing causal variant sets evaluated at the significance level of 2.5 × 10−6 for 
longitudinal continuous traits. Each LSRAT test was compared with GEE- B, S, C, O, E, 
A, respectively. Figure 2.2 presents the empirical power of LSRAT tests and GEE tests 
for longitudinal dichotomous traits evaluated at the same significance level. LSRAT tests 
have improved power compared to their corresponding GEE tests for longitudinal 
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continuous traits, especially for longitudinal dichotomous traits. Among them, LSRAT-
V, A, O has the most substantial power gain as compared with GEE-V, A, O.  
 
Figure 2.1. Power plots of variant-set tests(left panel) GEE-B, S, C and LSRAT-B, S, C; omnibus 
tests(right panel) GEE-O, E, A and LSRAT- O, E, A for continuous longitudinal traits. Each bar 
represents the empirical power estimated as the proportion of p values less than 𝛼𝛼 = 5 ×10 -6 of sample 
size 𝑛𝑛 =  2,500, 5,000, 7,500. The proportion of causal variants is set to be 5%, 20%, and 50% which were 
shown by three rows of each panel. The coefficients for the causal variants are 50% positive, 80% positive, 
and 100% positive which corresponds to the three columns of each panel. The effect size(|𝛽𝛽𝑖𝑖 | s) of the 
causal variants are set to be |𝛽𝛽𝑖𝑖| = 𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 |, where 𝑐𝑐 was set to 0.04 for 50% causal, 0.06 for 20% 





Figure 2.2. Power plots of variant-set tests(left panel) GEE-B, S, C and LSRAT-B, S, C; omnibus 
tests(right panel) GEE-O, E, A and LSRAT- O, E, A for dichotomous longitudinal traits. Each bar 
represents the empirical power estimated as the proportion of p values less than 𝛼𝛼 = 5 ×10 -6  of sample 
size 𝑛𝑛 =  2,500, 5,000, 7,500. The proportion of causal variants is set to be 5%, 20%, and 50% which were 
shown by three rows of each panel. The coefficients for the causal variants are 50% positive, 80% positive, 
and 100% positive which corresponds to the three columns of each panel. The effect size(|𝛽𝛽𝑖𝑖 | s) of the 
causal variants are set to be |𝛽𝛽𝑖𝑖| = 𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 |, where 𝑐𝑐 was set to 0.08 for 50% causal, 0.12 for 20% 
causal and 0.24 for 5% causal.  
 
Figure 2.3 and figure 2.4 present the empirical power of RSMMAT- B, S, C, O, E, A 
for testing causal variant sets evaluated at the significance level of 2.5 × 10−6 for 
longitudinal continuous and dichotomous traits. We compared their power with their 
prospective counterparts SMMAT B, S, C, O, E, A, respectively. For longitudinal 
continuous traits, because the prospective model is correctly specified, retrospective 
GLMM-based tests have similar power as prospective ones. For longitudinal 
dichotomous traits in which subjects were ascertained based on their baseline 
observations, the prospective modeling is misspecified. In this situation, RSMMAT tests 
have substantially increased power as compared with GLMM tests. The most notable 
increase of power is observed comparing the aggregated Cauchy association variant-set 
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test (RSMMAT-C and GLMM-C), where GLMM-C has substantially lesser power than 
RSMMAT-C. This is because the aggregated Cauchy association variant-set test is based 
on the P-values of each single variant test. And as was shown in the previous study[56], 
the GLMM-based single variant test is underpowered in ascertained phenotypes, which 
compromised the power of the aggregated test.  
 
Figure 2.3. Power plots of variant-set tests (left panel) GLMM-B, S, C and RSMMAT-B, S, C; 
omnibus tests (right panel) GLMM-O, E, A and RSMMAT- O, E, A for continuous longitudinal 
traits. Each bar represents the empirical power estimated as the proportion of p values less than 𝛼𝛼 = 5 ×10 
-6 of sample size 𝑛𝑛 =  2,500, 5,000, 7,500. The proportion of causal variants is set to be 5%, 20%, and 
50% which were shown by three rows of each panel. The coefficients for the causal variants are 50% 
positive, 80% positive, and 100% positive which corresponds to the three columns of each panel. The effect 
size(|𝛽𝛽𝑖𝑖 | s) of the causal variants are set to be |𝛽𝛽𝑖𝑖| = 𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖where 𝑐𝑐 was set to 0.04 for 50% causal, 





Figure 2.4. Power plots of variant-set tests (left panel) GLMM-B, S, C and RSMMAT-B, S, C; 
omnibus tests(right panel) GLMM -O, E, A and RSMMAT- O, E, A for dichotomous longitudinal 
traits. Each bar represents the empirical power estimated as the proportion of p values less than 𝛼𝛼 = 5 ×10 
-6 of sample size 𝑛𝑛 =  2,500, 5,000, 7,500. The proportion of causal variants is set to be 5%, 20%, and 
50% which were shown by three rows of each panel. The coefficients for the causal variants are 50% 
positive, 80% positive, and 100% positive which corresponds to the three columns of each panel. The effect 
size(|𝛽𝛽𝑖𝑖 | s) of the causal variants are set to be |𝛽𝛽𝑖𝑖| = 𝑐𝑐| log10 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 |, where 𝑐𝑐 was set to 0.08 for 50% 
causal, 0.12 for 20% causal and 0.24 for 5% causal.  
 
 
The power increases with the sample size and decreases when the proportion of 
causal signals of the same direction drops from 100% to 50% for all tests, but with the 
most considerable decrease observed for burden types of tests. Among the three types of 
variant-set tests, the ACAT-V tests are more powerful in the 5% causal scenario where 
the causal signal is sparse but less powerful when the signal is dense (20% and 50% 
causal). Burden tests are more powerful when the causal proportion is high (50%) and the 
signals are in the same direction (100% positive) for a small sample size (2.5k), but the 
advantage of burden tests diminishes as the sample size increases. For omnibus tests, all 
three types of the omnibus tests in general show similar power and robustness to the 
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direction and proportion of causal variants. SKAT-O has an advantage when the there is a 
large set of causal variants (50%) while ACAT-O gains advantage when the proportion of 
causal variants is small (5%). SKAT-E has slightly less powerful than SKAT-O but it is 
computationally more efficient. 
Comparing the performance of GEE-based tests and GLMM-based tests, the 
simulation results suggest that GLMM-based tests are slightly more powerful than GEE-
based tests for longitudinal continuous traits. This is due to the fact that the GLMM 
model fitted has correctly specified random components whereas GEE model used AR1 
correlation structure and sandwich estimator. On the other hand, GEE-based tests are 
much more powerful than GLMM-based tests for longitudinal dichotomous traits with 
efficient sampling. This suggests that GEE-based tests are more robust to ascertainment 
sampling than GLMM-based tests. Additionally, the retrospective analysis demonstrates 
more powerful gain than prospective tests in longitudinal dichotomous traits.  
 
2.5 Application: VACS Alcohol Use GWAS Data 
2.5.1 Association Analysis 
To illustrate the use of our proposed tests, we analyzed a GWAS data set of alcohol 
use disorder from VACS [57]. VACS is a longitudinal observational cohort study of both 
HIV-positive and uninfected veterans. It has the aim of understanding the role of 
psychiatric conditions including alcohol and other substance abuse in the clinical 
consequences of HIV infection. Our use of the VACS data was approved by both the 
Yale Human Research Protection Program and the Institutional Review Board of the 
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Veterans Affairs Connecticut Healthcare System. Our data source was alcohol use 
disorders identification test-consumption (AUDIT-C) questionnaire. This data is 
longitudinal as the questionnaire was collected over time for six clinic visits, on a total of 
2,470 patients. The AUDIT-C score is a reliable and valid measure to assess the risk of 
harmful alcohol use, which has been used in previous VACS studies. The score ranges 0 
to 12, where 0 reflects no alcohol use and evaluates three measures of alcohol 
consumption. These measures include the frequency of usual consumption, the quantity 
of usual consumption, and the frequency of binge drinking. The missing rate at each visit 
ranges from 3.0% to 58.3%. The average AUDIC-C score for HIV positive subjects is 
3.90 and for HIV negative subjects is 4.19.  
All samples were genotyped on the Illumina OmniExpress BeadChip and were 
imputed using 1000 Genome Phase 3 data as a reference panel using IMPUTE2[23]. We 
performed quality-control (QC) on the subjects and the genetic variants. A detailed 
description of the subject level QC process can be found in our previous study[56]. SNPs 
that satisfied all of the following QC conditions were included in this analysis: (1) call 
rate > 95%, (2) Hardy-Weinberg 𝜒𝜒 2 statistic P-value > 10-6. We annotated variants to 
genes using ANNOVAR [58].The resulting data set has 2,210 individuals who have both 
genotype and phenotype information and a total of 32,233 genes. Gender, age at baseline, 
HIV status, and top five principal components (PCs) were included as static covariates 
and the time of visit was included as a dynamic covariant. 
We performed genome-wide association gene-based testing for the longitudinal 
AUDIT-C score on 32,233 genes in a total of 2,210 subjects.  We considered GEE, 
LSRAT, GLMM and RSMMAT tests with adjustment for sex, baseline age, HIV status, 
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visit time and top five PCs. For each of the four types of tests (GEE, GLMM, LSRAT, 
RSMMAT), we consider three variant-set tests (B, S, C) and three omnibus tests (O, E, 
A). In total, we evaluated twenty-four tests. The genomic control inflation factors for the 
twelve tests ranges from 0.92 to 1.06.  
Table 2.3 summarizes genes identified by GEE model based prospective and 
retrospective variant-set and omnibus tests (GEE and LSRAT) with P-values less than 
5 × 10−5 in at least one longitudinal test. Table 2.4 summarizes genes identified by 
GLMM model based prospective and retrospective variant-set and omnibus tests (GLMM 
and RSMMAT) with P-values less than 10−4 in at least one longitudinal test. Gene 
UBE2L3 was identified as a top gene from both GEE model based tests and GLMM 
model based tests. This gene, encoding ubiquitin-conjugating enzyme E2, was recently 
reported in another GWA study to interact with alcohol consumption and was also 
significantly associated with lipid levels [59]. In a previous study, it was identified as an 
ethanol‐responsive gene in the prefrontal cortex in mice[60]. This suggests that UBE2L3 
could be implicated in alcoholism. Gene EFCAB10, located at 7q22.3, is another protein 
coding gene that was also identified among top genes in both models. An SNP located 
within this gene was formerly found in association with bipolar disorder [61], a 
commonly co-occurred disorder with alcoholism [62]. Gene NPIPB3 is a protein coding 
gene located at 16p12.2. This gene was reported to be associated with extremely 
impulsively violence and aggressive behavior in males. As was suggested in previous 
studies, the frequently observed comorbidity of alcohol use disorder and impulsive 
aggression implicate a shared genetic basis underlies these two disorders [63–65]. In 
another study, an intron variant (rs12923444) located in the promoter region of NPIPB3 
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was found significantly associated with depression in a Genome-wide meta-analysis[66]. 
Our tests found gens to be significantly associated with alcohol use disorder that have 
been previously shown to be associated with alcoholism or major psychiatric disorders 





Table 2.3. Top genes with P-value < 5×10-5 in at least one of the GEE and LSRAT in the VACS 
sample. * denotes protein coding gene, bold denotes the minimum P-value for the given gene. The smallest 
P-value among all tests at the given genes are in bold. 
 
Prospective Retrospective 













MIR4454 10 4 4.49E-04 1.44E-05 4.65E-05 3.25E-05 6.95E-05 3.15E-05 1.28E-03 8.73E-05 3.32E-04 1.61E-04 3.48E-04 1.98E-04 
UBE2L3* 324 22 3.52E-05 2.63E-03 1.50E-02 6.11E-05 2.43E-04 7.52E-05 1.97E-05 4.08E-04 1.02E-02 5.46E-05 1.73E-04 5.89E-05 
C9orf40* 15 9 8.34E-02 7.90E-02 1.03E-03 1.30E-01 3.68E-02 4.57E-03 8.00E-02 6.81E-02 2.21E-05 1.28E-01 2.36E-02 7.70E-05 
LINC01455 136 5 7.31E-02 5.55E-03 6.10E-03 1.23E-02 1.89E-02 9.14E-03 7.18E-02 2.90E-03 4.29E-05 6.22E-03 3.09E-03 1.45E-04 
ZNF33A* 202 10 8.58E-02 9.30E-04 5.04E-05 2.16E-03 2.33E-03 2.54E-04 7.85E-02 4.71E-04 8.40E-04 1.09E-03 2.57E-03 9.24E-04 
ZNF25* 130 10 4.17E-01 6.41E-02 5.45E-05 9.97E-02 1.31E-02 3.07E-04 3.82E-01 4.79E-02 9.66E-04 7.71E-02 1.54E-02 3.17E-03 
TMEM198B 14 12 5.58E-04 3.83E-02 5.51E-02 9.62E-04 2.62E-03 1.31E-03 5.93E-05 1.06E-02 2.27E-02 1.72E-04 5.08E-04 1.87E-04 
NPIPB4* 8 16 6.85E-05 8.43E-03 1.38E-02 1.41E-04 5.64E-04 1.51E-04 8.65E-05 7.45E-03 2.14E-02 1.99E-04 8.78E-04 2.70E-04 
EGF* 483 4 5.86E-01 3.72E-04 6.98E-05 9.84E-04 7.40E-04 2.76E-04 6.13E-01 2.44E-04 7.82E-04 6.36E-04 5.21E-04 5.68E-04 
PROX1-AS1 233 1 6.63E-01 2.68E-02 1.02E-02 5.45E-02 4.07E-02 2.69E-02 6.66E-01 2.12E-02 8.64E-05 4.19E-02 2.43E-02 2.96E-04 
EFCAB10* 8 7 1.29E-01 5.20E-04 1.83E-03 1.40E-03 1.18E-03 1.21E-03 9.56E-02 8.86E-05 1.30E-04 2.47E-04 1.28E-04 1.62E-04 
 
Table 2.4. Top genes with P-value < 10-4 in at least one of the GLMM and RSMMAT in the VACS 
sample. * denotes protein coding gene, bold denotes the minimum P-value for the given gene. The smallest 
P-value among all tests at the given genes are in bold. 
 
Prospective Retrospective 













UBE2L3* 324 22 3.59E-05 1.32E-03 1.40E-02 9.44E-05 3.31E-04 1.13E-04 5.27E-05 1.09E-03 1.31E-02 1.41E-04 4.46E-04 1.58E-04 
LINC01455 136 5 9.13E-02 4.66E-03 6.55E-05 9.76E-03 7.27E-03 2.48E-04 9.80E-02 4.58E-03 3.84E-05 9.66E-03 6.04E-03 1.40E-04 
PROX1-AS1 233 1 6.86E-01 1.48E-02 8.44E-05 2.83E-02 1.53E-02 3.20E-04 6.81E-01 1.56E-02 4.55E-05 3.10E-02 1.83E-02 1.66E-04 
LINC00467 219 1 9.58E-05 3.11E-03 1.29E-02 2.57E-04 7.81E-04 2.95E-04 6.53E-05 3.03E-03 1.21E-02 1.78E-04 5.53E-04 2.02E-04 
C9orf40* 15 9 1.04E-01 1.00E-01 1.33E-04 1.66E-01 4.15E-02 4.98E-04 1.00E-01 1.01E-01 7.22E-05 1.64E-01 4.06E-02 2.63E-04 
EFCAB10* 8 7 1.81E-01 1.16E-04 5.59E-04 3.14E-04 2.34E-04 2.97E-04 1.69E-01 9.19E-05 3.99E-04 2.54E-04 1.66E-04 2.24E-04 
LOC101927






2.5.2 Pathway and eQTL Enrichment Analysis 
We performed pathway analysis on the SNPs contained in the top genes for which at 
least one of the longitudinal tests had a P-value < 5 × 10−5 using METACORE. Of the 
top ten significant pathways we found, four were particularly of interests. The first one is 
HTR2A (alias 5-HT2A) signaling, which belongs to neurophysiological process in the 
nervous system. HTR2A receptor agonist are emerging as a popular therapeutic treatment 
for alcohol dependence and other neuropsychiatric conditions, and it was studied to 
normalize dysregulated GABAergic signaling [67]. The second one is canonical WNT 
signaling pathway, which plays a vital role in neural cell proliferation during neural 
development. This pathway has been suggested by many studies to be associated with 
major psychiatric disorders, including bipolar disorder and schizophrenia [68,69]. The 
third and fourth pathways are adenosine A1 and adenosine A3 receptor signaling. 
Adenosine plays a crucial role in regulating neural activity in the central nervous system 
and it modulates many neurotransmitters. It has been found to be central to many 
pathophysiological processes including drug dependence and alcohol abuse [70,71]. 
Overall, these four significant pathways all have been shown previously to be associated 
with major psychiatric disorders and alcoholism, verifying our model is capable of 
identifying biologically relevant loci.  
Next, we performed an enrichment analysis to see if the top genes from our analysis 
are likely to regulate brain gene expression. Previous studies have shown that genes 
regulating brain tissue regulation are useful in understating the basis of psychiatric 
disorders [72]. The cis-eQTLs of 13 human brain regions reported from the GTEx project 
were considered in the analysis. We performed Fisher’s exact test to examine the 
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enrichment of brain region eQTLs (FDR < 0.05) in the SNPs contained in the top genes 
from GEE and LSRAT test. Among the brain regions, three brain regions showed 
significant enrichment: anterior cingulate cortex (odds ratio = 9.40, P-val < 2.20×10-16), 
cerebellar hemisphere (odds ratio = 5.53 , P-val = < 2.2×10-16), and cerebellum(odds 
ratio = 3.97 , P-val <  2.20×10-16These three brain regions were also significantly 
enriched in top genes identified from GLMM and RSMMAT tests: anterior cingulate 
cortex (odds ratio = 4.48, P-val < 2.20×10-16), cerebellar hemisphere (odds ratio = 2.26, 
P-val = 1.01×10-10) and cerebellum (odds ratio =1.76 , P-val =1.02×10-6 ).These results 
show that the top genes identified from our tests are likely to regulate gene expression in 




We have developed and implemented LSRAT and RSMMAT, two families of 
retrospective variant-set tests for longitudinally measured continuous and binary traits in 
large scale genome wide association studies. In particular, LSRAT is a family of GEE 
model based association tests which include three variant-set level tests: the burden test 
(LSRAT-B), SKAT (LSRAT-S), and ACAT (LSRAT-C), as well as three omnibus tests 
that combines burden and SKAT with different strategies: LSRAT-O, LSRAT-E, and 
LSRAT-A. For comparison we also proposed RSMMAT, the mixed model counterparts 
of LSRAT, which introduced retrospective analysis to the existing prospective variant-set 
tests (SMMAT). Both LSRAT and RSMMAT are retrospective tests that are constructed 
76 
 
based on the genotype model given the phenotype and covariates. LSRAT models the 
within subject dependence with working covariance matrix whereas RSMMAT captures 
it with random effects. These two families of retrospective tests for longitudinal traits 
have several advantages: (1) they are robust against trait model misspecification; (2) they 
are able to adjust both static and time-varying covariates; (3) they allow for related 
subjects and account for population structure; and (4) they are computationally more 
efficient than existing prospective approaches. They provide important tools for the study 
of the genetic mechanism of longitudinal phenotypes especially for the psychiatric 
disorders where the temporal course and developmental pattern of the traits are of 
valuable information and has been less studied.  
LSRAT also has limitations. As mentioned previously, SMMAT p values are 
computed based on asymptotic distributions, which may be violated in small samples, 
especially for binary traits. Additionally, the p value computed for SMMAT-E relies on 
the assumption that the working correlation specified is the true correlation structure. 
However, benefitting from the robustness of GEE estimators to correlation structure 
model misspecification, the simulation results showed that LSRAT-E p-value maintained 
a correct type I error rate even when the correlation structure is not correctly specified.  
We applied LSRAT and RSMMAT to longitudinal association analysis of alcohol use 
in the VACS data. Pathway analysis of the top genes identified four significant pathways 
associated with longitudinal alcohol use: the HTR2A signaling pathway, the canonical 
WNT signaling pathway, the adenosine A1 and adenosine A2 signaling pathways. 
Enrichment analysis of brain region eQTLs demonstrated that top genes comprised of 
SNPs are enriched with eQTLs from two brain regions: anterior cingulate cortex and 
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cerebellum. The anterior cingulate cortex which mediates willed control of actions, was 
previously found to contribute to drug addiction[73]. Recently, it was studied that the 
thickness of anterior cingulate cortex is associated with alcohol use patterns [74]. As the 
cerebellar dysfunction and degeneration are commonly observed in alcoholics, the 
function of which has long been considered to be associated with alcoholism [75]. There 
are accumulating evidence that connect cerebellum to genetic risk for developing alcohol 
use disorder. In a recent study, it was demonstrated the strong influence of cerebellar in 
the susceptibility to alcohol abuse and the cerebellar has been highlighted as a target for 
pharmacological treatment of alcohol use disorder [76].  
In summary, LSRAT and RSMMAT provide a retrospective association framework 
for variant-set tests in large-scale genome-wide association for longitudinal traits. As the 
electronic health records become more available, these two families of tests will serve as 
powerful tools to uncover the mechanism of genes that control the developmental 
trajectories of traits, especially for psychiatric traits where the progression and 
developmental trajectories convey more valuable and reliable information than single 
time points measures. We expect a future extension of the proposed methods towards 
functional modeling of the genetic temporal effects as well as separately testing gene-
environment interaction in longitudinal GWA studies to improve the discovery process of 





Gene-graph based imputation method for 
single-cell RNA sequencing data 
3.1 Abstract 
Single-cell RNA sequencing technology provides an opportunity to study gene 
expression at single-cell resolution. However, prevalent dropout events result in high data 
sparsity and noise that may obscure downstream analyses in single-cell transcriptomic 
studies. We propose a novel method, G2S3, that imputes dropouts by borrowing 
information from adjacent genes in a sparse gene graph learned from gene expression 
profiles across cells. We applied G2S3 and ten existing imputation methods to eight 
single-cell transcriptomic datasets to compare their performance. Our results 
demonstrated that G2S3 is superior in recovering true expression levels, identifying cell 
subtypes, reconstructing cell trajectories, identifying differentially expressed genes, and 
recovering gene correlation relationships, especially for genes with relatively low 
expression levels. Moreover, G2S3 is computationally efficient for imputation in large-
scale single-cell transcriptomic datasets. 
 
3.2 Introduction 
Singe-cell RNA sequencing (scRNA-seq) has emerged as a state-of-the-art technique 
for transcriptome analysis. Compared to bulk RNA-seq that measures the average gene 
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expression profile of a mixed cell population, scRNA-seq measures expression profile of 
individual cells and thus describes cell-to-cell stochasticity in gene expression. 
Applications of this technology in humans have revealed rare and novel cell types [77–
79], cell population composition changes [80], and cell-type specific transcriptomic 
changes [79,81] that are associated with diseases. These findings have great potential to 
promote our understanding of cell function, disease pathogenesis, and treatment response 
for more precise therapeutic development [82,83]. However, analysis of scRNA-seq data 
can be challenging due to low library size, high noise level, and prevalent dropout events 
[84]. Particularly, dropouts lead to an excessive number of zeros or close to zero values 
in the data, especially for genes with low or moderate expression. These inaccurately 
measured gene expression levels may obscure downstream quantitative analyses such as 
cell clustering and differential expression analyses [82]. 
In the past few years, several imputation methods have been developed to recover 
dropout events in scRNA-seq data. A group of methods, including kNN-smoothing [85], 
MAGIC [86], scImpute [87], drImpute [88], and VIPER [89], assess between-cell 
similarity and impute dropouts in each cell using its similar cells. Specifically, kNN-
smoothing uses step-wise k-nearest neighbors to aggregate information from the 𝑘𝑘 closest 
neighboring cells of each cell for imputation. MAGIC constructs an affinity matrix of 
cells and aggregates gene expression across similar cells via data diffusion to impute 
gene expression for each cell [86]. scImpute infers dropout events based on the dropout 
probability estimated from a Gamma-Gaussian mixture model and only imputes these 
events by borrowing information from similar cells within cell clusters detected by 
spectral clustering [87]. drImpute identifies similar cells through K-means clustering and 
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performs imputation by averaging expression levels of cells within the same cluster [88]. 
While these imputation methods improved the quality of scRNA-seq data to some extent, 
they were found to eliminate natural cell-to-cell stochasticity which is an important piece 
of information available in scRNA-seq data compared to bulk RNA-seq data [89]. VIPER 
overcomes this limit by considering a sparse set of neighboring cells for imputation to 
preserve variation in gene expression across cells [89]. In general, imputation methods 
that borrow information across similar cells tend to intensify subject variation in scRNA-
seq datasets with multiple subjects, which causes cells from the same subject to be more 
similar than those from different subjects. To address this issue, SAVER borrows 
information across similar genes instead of cells to impute gene expression using a 
penalized regression model [90]. There are other methods that leverage information from 
both genes and cells. For example, ALRA imputes gene expression using low-rank 
matrix approximation [91], and scTSSR uses two-side sparse self-representation matrices 
to capture gene-to-gene and cell-to-cell similarities for imputation [92]. In addition, 
machine learning-based methods, such as autoImpute [93], DAC [94], deepImpute [95] 
and SAUCIE [96], use deep neural network to impute dropout events. While 
computationally more efficient, these methods were found to generate false-positive 
results in differential expression analyses [97]. Recently, an ensemble approach, 
EnImpute, was developed to integrate multiple imputation methods using weighted 
trimmed mean [98]. 
In this article, we develop G2S3, a sparse and smooth signal of gene graph-based 
method that imputes dropout events in scRNA-seq data by borrowing information across 
similar genes. G2S3 learns a sparse graph representation of gene-gene relationships from 
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the data, in which each node represents a gene and is associated with a vector of 
expression levels in all cells considered as a signal on the graph. The graph is then 
optimized under the assumption that signals change smoothly between connected genes. 
Based on this graph, a transition matrix for a random walk is constructed so that the 
transition probabilities between genes with similar expression levels across cells are 
higher. A random walk on this graph imputes the expression level of each gene using the 
weighted average of expression levels from itself and adjacent genes in the graph. In this 
way, G2S3, like SAVER, makes use of gene-gene relationships to recover the true 
expression levels. However, unlike SAVER which uses a penalized regression model for 
imputation, G2S3 optimizes the gene graph structure using graph signal processing that 
captures nonlinear correlations among genes and is robust to outliers in the data. The 
computational complexity of the G2S3 algorithm is a polynomial of the total number of 
genes in the graph, so it is computationally efficient, especially for large scRNA-seq 
datasets with hundreds of thousands of cells. 
 
3.3 Material and methods 
3.3.1 G2S3 algorithm 
To borrow information from similar genes for data imputation, G2S3 first builds a 
sparse graph representation of gene network under the assumption that expression levels 
change smoothly between closely connected genes. Let 𝑋𝑋 = [𝑥𝑥1, 𝑥𝑥2, … , 𝑥𝑥𝑚𝑚] ∈ ℝ𝑛𝑛×𝑚𝑚 
denote the observed transcript counts of 𝑚𝑚 genes in 𝑛𝑛 cells, where the column 𝑥𝑥𝑗𝑗 ∈ ℝ𝑛𝑛 
represents the expression vector of gene 𝑗𝑗, for 𝑗𝑗 = 1, … ,𝑚𝑚. We regard each gene 𝑗𝑗 as a 
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vertex 𝑉𝑉𝑗𝑗 in a weighted gene graph 𝐺𝐺 = (𝑉𝑉,𝐸𝐸), in which the edge between genes 𝑗𝑗 and 𝑘𝑘 
is associated with a weight 𝑊𝑊𝑗𝑗𝑗𝑗. 
The gene graph is then determined by the weighted adjacency matrix 𝑊𝑊 ∈ ℝ+𝑚𝑚×𝑚𝑚 . 
G2S3 searches for a valid adjacency matrix 𝑊𝑊 from the space 
𝒲𝒲 = {𝑊𝑊 ∈ ℝ+𝑚𝑚×𝑚𝑚:   𝑊𝑊 = 𝑊𝑊𝑇𝑇, diag(𝑊𝑊) = 0} 
that is optimal under the assumption of smoothness and sparsity on the graph. To achieve 
this, we use the objective function adapted from Kalofolias’s model [99]: 
min
𝑊𝑊∈𝒲𝒲
   ‖𝑊𝑊 ∘ 𝑍𝑍‖1,1 − 1𝑇𝑇 log(𝑊𝑊1) +
1
2
‖𝑊𝑊‖𝐹𝐹2 ,                                           (1) 
where 𝑍𝑍 ∈ ℝ+𝑚𝑚×𝑚𝑚  is the pairwise Euclidean distance matrix of genes, defined as 𝑍𝑍𝑗𝑗𝑗𝑗 =
�𝑥𝑥𝑗𝑗 − 𝑥𝑥𝑗𝑗�
2
, ‖⋅‖1,1 is the elementwise L-1 norm, ∘ is the Hadamard product, and ‖⋅‖𝐹𝐹 is 
the Frobenius norm. The first term in Eq. (1) is equivalent to 2 tr(𝑋𝑋𝑇𝑇𝐿𝐿𝑋𝑋) that quantifies 
how smooth the signals are on the graph, where 𝐿𝐿 is the graph Laplacian and tr(. ) is the 
trace of a matrix. This term penalizes edges between distant genes, so it prefers to put a 
sparse set of edges between the nodes with a small distance in 𝑍𝑍. The second term in Eq. 
(1) represents the node degree which requires the degree of each gene to be positive to 
improve the overall connectivity of the gene graph. The third term in Eq. (1) controls 
sparsity to penalize the formation of large edges between genes. 
The optimization of Eq. (1) can be solved via primal dual techniques [100]. We rewrite 
Eq. (1) as 
min
𝑤𝑤∈𝜔𝜔
   1{𝑤𝑤≥0} + 2𝑤𝑤𝑇𝑇𝑧𝑧 − 1𝑇𝑇 log(𝑑𝑑) + ‖𝑤𝑤‖2, where 𝜔𝜔 = �𝑤𝑤 ∈ ℝ+
𝑚𝑚(𝑚𝑚−1)
2 � ,            (2) 
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where 𝑤𝑤  and 𝑧𝑧 are vector forms of 𝑊𝑊  and 𝑍𝑍 , respectively, 𝑑𝑑 = 𝐾𝐾𝑤𝑤 ∈ ℝ𝑚𝑚  and 𝐾𝐾  is the 
linear operator that satisfies 𝑊𝑊1 = 𝐾𝐾𝑤𝑤. After obtaining the optimal 𝑊𝑊, a lazy random walk 
matrix can be constructed on the graph: 
𝑀𝑀 = (𝐷𝐷−1𝑊𝑊 + 𝐼𝐼)/2,                                                                   (3) 
where 𝐷𝐷 is an 𝑚𝑚-dimensional diagonal matrix with 𝐷𝐷𝑗𝑗𝑗𝑗 = ∑ 𝑊𝑊𝑗𝑗𝑗𝑗𝑗𝑗 , the degree of gene 
𝑗𝑗, and 𝐼𝐼 is the identity matrix. 
The imputed count matrix 𝑋𝑋imputed is then obtained by taking a 𝑡𝑡-step random walk on 
the graph which can be written as 
𝑋𝑋imputed𝑇𝑇 = 𝑀𝑀𝑡𝑡 × 𝑋𝑋𝑇𝑇.                                                                 (4) 
By default, G2S3 takes a one-step random walk (𝑡𝑡 = 1) to avoid over-smoothing. We 
also implement an option of tuning the hyperparameter 𝑡𝑡 based on an objective function 
that minimizes the MSE between the imputed and observed data, i.e. 
𝑡𝑡∗ = argmin
𝑡𝑡
 ‖𝑀𝑀𝑡𝑡𝑋𝑋𝑇𝑇 − 𝑋𝑋𝑇𝑇‖. 
Similar to other diffusion-based methods, G2S3 spreads out counts while keeping the 
sum constant in the random walk step. This results in the average value of non-zero matrix 
entry decreasing after imputation. To match the observed expression at the gene level, we 
rescale the values in 𝑋𝑋imputed so that the mean expression of each gene in the imputed data 





3.3.2 Real datasets 
We evaluated and compared the performance of G2S3 and ten existing imputation 
methods using datasets from eight scRNA-seq studies. Among them, four datasets were 
generated using the UMI techniques and four were generated by non-UMI-based 
techniques. 
Reyfman refers to the scRNA-seq dataset of human lung tissue from healthy transplant 
donors in Reyfman et al. [101]. The raw data include 33,694 genes and 5,437 cells. To 
generate the reference dataset, we selected cells with a total number of UMIs greater than 
10,000 and genes that have nonzero expression in more than 20% of cells. This ended up 
with 3,918 genes and 2,457 cells. 
PBMC refers to human peripheral blood mononuclear cells from a healthy donor 
stained with TotalSeq-B antibodies generated by the high-throughput droplet-based system 
[102]. This dataset was downloaded from 10x Genomics website 
(https://support.10xgenomics.com/single-cell-gene-expression/datasets). The raw data 
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include 33,538 genes and 7,865 cells. To generate the reference dataset, we selected cells 
with a total number of UMIs greater than 5,000 and genes that have nonzero expression in 
more than 20% of cells. This ended up with 2,308 genes and 2,081 cells. 
Zeisel refers to the scRNA-seq dataset of mouse cortex and hippocampus in Zeisel et 
al. [103]. The raw data include 19,972 genes and 3,005 cells. To generate the reference 
dataset, we selected cells with a total number of UMIs greater than 10,000 and genes that 
have nonzero expression in more than 40% of cells. This ended up with 3,529 genes and 
1,800 cells. 
Chu refers to the dataset investigating the separation of cell subpopulations in Chu et 
al. [104]. It measured gene expression of 1,018 cells including undifferentiated H1 and H9 
human ES cell lines and the H1-derived progenitors. The cells were annotated with seven 
cell subtypes: neuronal progenitor cells (NP), definitive endoderm cells (DE), endothelial 
cells (EC), trophoblast-like cells (TB), human foreskin fibroblasts (HF), and 
undifferentiated H1 and H9 human ES cells. We performed preliminary filtering to remove 
genes expressed in less than 10% of cells, which resulted in 13,829 genes. 
Petropoulos refers to the dataset studying cell lineage in human embryo development 
in Petropoulos et al. [105]. It measured expression profiles of 26,178 genes in 1,529 cells 
from 88 human embryos. Cells were labeled as E3-E7 representing their embryonic day. 
We performed preliminary filtering to remove genes expressed in less than 5 cells and cells 
with less than 200 expressed genes. After the filtering, we ended up with 22,934 genes and 
1,529 cells. 
Trapnell refers to the dataset studying the transcriptional dynamics of human 
myoblasts in Trapnell et al. [106]. scRNA-seq data were collected on undifferentiated 
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primary human myoblasts at time 0 and differentiating myoblasts at 24, 48 and 72 hours. 
Most of the cells are mature myotubes 72 hours after inducing differentiation. The raw data 
include 47,192 genes and 372 cells. We performed preliminary filtering to remove genes 
expressed in less than 10% of cells, which resulted in 13,286 genes. 
Paul refers to the dataset from a study on the transcriptional differentiation landscape 
of myeloid progenitors [107]. This dataset includes 3,451 informative genes and 2,730 cells. 
We used this dataset to evaluate the performance of imputation methods in restoring gene 
regulatory relationships between well-known regulators. 
Buettner refers to the dataset in Buettner et al. [108]. This dataset includes mouse ES 
cells labeled by three cell cycle phases – G1, S, and G2/M via flow sorting. The raw data 
include 9,571 genes and 288 cells. We used this dataset to evaluate the performance of 
imputation methods in enhancing gene correlations between periodic marker genes of cell 
cycle phase. We performed preliminary filtering to remove genes expressed in less than 
20% of cells, which resulted in 13,355 genes. 
3.3.3 Performance evaluation 
Expression data recovery. 
 We first compared the method performance in recovering true expression levels using 
down-sampled datasets. Down-sampling was performed on three independent UMI-based 
scRNA-seq datasets (Reyfman, PBMC, and Zeisel) to generate benchmarking observed 
datasets in a similar framework to previous studies [90,95]. In each dataset, we selected a 
subset of genes and cells with high expression to be used as the reference dataset and treated 
them as the true expression. Details on the thresholds chosen to generate the reference 
datasets are described in the “Real datasets” section. However, unlike previous studies that 
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simulated down-sampled datasets from models with certain distributional assumptions [90] 
which may incur modeling bias, we performed random binary masking of UMIs in the 
reference datasets to mimic the inefficient capturing of transcripts in dropout events. The 
binary masking process masked out each UMI independently with a given probability. In 
each reference dataset, we randomly masked out 80% of UMIs to create the down-sampled 
observed dataset. 
All imputation methods were applied to each down-sampled dataset to generate 
imputed data separately. Because imputation methods such as SAVER and MAGIC output 
the normalized library size values, we performed library size normalization on all imputed 
data. We calculated the gene-wise Pearson correlation and cell-wise Spearman correlation 
between the reference data and the imputed data generated by each imputation method. 
The correlations were also calculated between the reference data and the observed data 
without imputation to provide a baseline for comparison. To investigate whether the 
performance depends on the true expression level, we stratified genes into three categories: 
widely, mildly, and rarely expressed genes, based on the proportion of cells expressing 
each gene in the down-sampled observed datasets. Specifically, widely expressed genes 
are those with non-zero expression in more than 80% of cells, rarely expressed genes are 
those with non-zero expression in less than 30% of cells, and mildly expressed genes are 
those that lie in between. The gene-wise and cell-wise correlations in each stratum were 
used to demonstrate the impact of expression level on the performance of imputation 
methods. 
 
Restoration of cell subtype separation.  
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We applied all imputation methods to the Chu dataset to evaluate their performance in 
separating different cell types. A good imputation method is expected to stabilize within 
cell-subtype variation (intra-subtype distance) while maintaining between cell-subtype 
variation (inter-subtype distance). Principal component analysis was conducted on the raw 
and imputed data for dimension reduction. We calculated the inter-subtype distance as the 
Euclidian distance between cells from different cell types, and the intra-subtype distance 
as the distance between cells of the same cell type, using the top 𝐾𝐾 PCs of the data, for 
𝐾𝐾 = 1, … ,50. The ratio of the average inter-subtype distance to the average intra-subtype 
distance was used to quantify the performance. The higher this ratio is, the better 
performance the method has. We also calculated silhouette coefficient, a composite index 
reflecting both the compactness and separation of different cell types, using the top PCs 
and the true cell subtype labels. The silhouette coefficient ranges from -1 to 1 with a higher 
value indicating a better matching with the cell subtypes and a value close to zero indicating 
random clustering [109]. To demonstrate the comparison using cell clustering results, we 
visualized the raw and imputed data with UMAP plots using the top three PCs and colored 
cells by the cell subtype labels. The normalized mutual information (MI) and adjusted rand 
index (RI) were used to measure the consistency between cell clustering results and true 
cell subtype labels. To demonstrate cell subtype separation based on cell subtype marker 
genes, we further displayed DE and H1/H9 cells by plotting the log-transformed counts 
using their marker genes [104]: GATA6, a marker gene of DE cells, and NANOG, a marker 
gene of H1/H9 cells. 
 
Improvement in cell trajectory inference.  
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We assessed the performance of imputation methods in restoring cell trajectory using 
human preimplantation embryos from different embryonic days in the Petropoulos dataset. 
We considered the actual embryonic days to represent the true cell differentiation stage or 
age. Monocle 2 was used to infer pseudo-time from the normalized raw and imputed data 
[110]. To measure the consistency between the actual embryonic days and the 
reconstructed pseudo-time, we calculated the pseudotemporal ordering score (POS) and 
Kendall rank correlation coefficient (Cor). Cell trajectories were visualized by embedding 
cells into two-dimensional space using reversed graph embedding, a recently developed 
machine learning method to reconstruct complex single-cell trajectories [110]. 
 
Improvement in differential expression analysis.  
To assess the performance in identifying differentially expressed genes, we compared 
gene expression between two cell subtypes: NP and H1 cells, using both imputed scRNA-
seq and bulk RNA-seq data from the Chu dataset. We also compared gene expression 
profiles of undifferentiated myoblasts to mature myotubes collected 72 hours after inducing 
differentiation from the Trapnell dataset. The raw and imputed data were normalized and 
log-transformed before evaluation. We used t-test in the bulk RNA-seq data to identify 
differentially expressed genes and selected the top 200 genes as ground truth. We then 
performed differential analysis in the scRNA-seq data using the same test. All the 
differential expression analysis in the scRNA-seq data was performed using the Seurat R 
package (version 3.0) with a default threshold to keep genes with at least 1.5-fold change. 
The predictive power of differentially expressed genes identified in the raw and imputed 




Gene correlation relationship restoration.  
We finally evaluated the method performance by investigating the enhancement in gene 
regulatory relationships using the Paul dataset and the recovery of gene-gene correlations 
between periodic marker genes in the Buettner dataset. In the Paul dataset, we 
reconstructed GRN among a set of regulators with known inhibitory and activatory 
relationships in blood development [94] with the raw and imputed datasets by different 
methods, using two GRN inference algorithms, GENIE3 and PPCOR. The prediction 
accuracy of each method was evaluated by comparing the inferred GRN to the ground-
truth network using AUPRC. The AUPRC ratio was calculated by dividing AUPRC by 
that of a random predictor and the process was repeated for 50 times. The estimated 
pairwise correlations between genes using the raw unimputed and imputed data by each 
method were compared for performance evaluation. The Beuttner dataset contains 67 
periodic marker genes with peak expression in G1/S and G2/M phases established in a 
previous study [111]. As marker gene expression varies over cell cycle, we expect pairs of 
periodic genes whose expression peak during the same cell cycle phase to be positively 
correlated, and pairs of genes whose expression peak at different phases to be negatively 
correlated. Pairwise correlations were calculated in the raw and imputed data by each 
method. The proportion of gene pairs with correct direction of correlation was used to 
compare the method performance. 
3.4 Results 
3.4.1 Evaluation overview 
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We evaluated and compared the performance of G2S3 and ten existing imputation 
methods, SAVER, kNN-smoothing, MAGIC, scImpute, VIPER, ALRA, scTSSR, DCA, 
SAUCIE and EnImpute, in terms of (1) expression data recovery, (2) cell subtype 
separation, (3) cell trajectory inference, (4) differential gene identification, and (5) gene 
regulatory and correlation relationship recovery. We applied these methods to eight 
scRNA-seq datasets that can be classified into five categories corresponding to the five 
criteria described above. The first category includes three unique molecular identifier 
(UMI)-based datasets in which down-sampling was performed to assess the method 
performance in recovering true expression levels. These datasets are the Reyfman dataset 
from human lung tissue [101], the peripheral blood mononuclear cell (PBMC) dataset from 
human peripheral blood [102], and the Zeisel dataset from mouse cortex and hippocampus 
[103]. The second category was used to evaluate the method performance in separating 
different cell types. It includes the Chu dataset of human embryonic stem (ES) cell-derived 
lineage-specific progenitors from seven known cell subtypes [104]. The third category was 
used to reconstruct cell trajectory. It includes the Petropoulos dataset of cells from human 
preimplantation embryos collected on different embryonic days [105]. The fourth category 
was chosen to evaluate the method performance in identifying differentially expressed 
genes. It includes the Chu dataset which is also included in the second category and the 
Trapnell dataset of differentiating human myoblasts [106]. The last category includes two 
datasets to evaluate the method performance in recovering gene regulatory and correlation 
relationship among known regulators and marker genes. These datasets are the Paul dataset 
that contains a set of well-known transcriptional regulators of myeloid progenitor 
populations [107], and the Buettner dataset that contains 67 periodic marker genes whose 
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expression level varies over cell cycle [108]. Table 1 summarizes the main features of all 
eight datasets. A more detailed description of these datasets is provided in the “Real 
datasets” section. 
Table 3.1. Detailed information on the eight scRNA-seq datasets used to compare the performance of 
imputation methods. * URL to access the dataset: https://support.10xgenomics.com/single-cell-gene-
expression/datasets 
Experiment 
Category Dataset # Cells Sample Type Organism Technique UMI Accession 
Expression 
data recovery 
Reyfman [23] 5,437 Lung tissue Homo Sapiens Drop-seq Yes 
GEO 
(GSE122960) 
PBMC  [24] 7,865 Peripheral blood mononuclear cells 
Homo 
Sapiens Drop-seq  Yes 
10x 
Genomics* 
Zeisel [25] 3,005 Brain tissue Mus Musculus Drop-seq  Yes Zeisel et al. 
Cell subtype 




















Chu [26] 1,018 Embryonic stem cells 
Homo 
Sapiens Fluidigm C1 No 
GEO 
(GSE75748) 













Musculus MARS-seq Yes Paul et al. 
Buettner [30] 288 Staged embryonic cells 
Mus 





3.4.2 Hyperparameter tuning in G2S3 
The G2S3 algorithm used graph signal processing to learn a gene graph and performed 
a 𝑡𝑡-step random walk to borrow information from neighboring genes for imputation. The 
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optimal value of the hyperparameter 𝑡𝑡 was selected by minimizing the mean squared error 
(MSE) between the imputed and observed data, which was also used in a previous study 
on diffusion-based imputation method [112]. We performed down-sampling on each 
dataset from the first category (Reyfman, PBMC and Zeisel) and evaluated the MSE as 
well as the gene-wise and cell-wise correlations of the G2S3 imputed data with reference 
data, for 𝑡𝑡 = 1, … ,10. Fig S3.1 shows the coefficient of variation (CV) of gene expression 
before and after down-sampling. In all datasets, although the CV of gene expression 
increased slightly after down-sampling, the correlation between the CV before and after 
down-sampling was 0.79 or higher, demonstrating that the down-sampled data well 
preserved the mean-variance relationship in the reference data. Fig S3.2A shows that the 
optimal value of 𝑡𝑡 is 1 in all three datasets based on the minimization of MSE. In addition, 
the one-step random walk in G2S3 achieved the greatest gene-wise and cell-wise 
correlations with the reference data (Fig S3.2B). This optimal choice of 𝑡𝑡 was consistent 
with the hyperparameter selected by another diffusion-based imputation method [112]. 
 
3.4.3 Expression data recovery in down-sampled datasets 
We conducted down-sampling on datasets from the first category (Reyfman, PBMC 
and Zeisel) to assess the performance of all eleven imputation methods in recovering true 
expression levels. Fig S3.1 shows the coefficient of variation (CV) of gene expression 
before and after down-sampling. In all datasets, although the CV of gene expression 
increased slightly after down-sampling, the correlation between the CV before and after 
down-sampling was 0.79 or higher, demonstrating that the down-sampled data well 
preserved the mean-variance relationship in the reference data. Fig 3.1 shows the gene-
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wise Pearson correlation and cell-wise Spearman correlation between the imputed and 
reference data from each dataset. The correlation between the observed data without 
imputation and reference data was set as a benchmark. In all datasets, G2S3 consistently 
achieved the highest correlation with the reference data at both gene and cell levels, and 
SAVER and scTSSR had slightly worse performance. EnImpute had comparable 
performance to G2S3 based on the cell-wise correlation but performed worse than G2S3, 
SAVER and scTSSR based on the gene-wise correlation. VIPER performed well in the 
Reyfman and PBMC datasets but not in the Zeisel dataset based on the gene-wise 
correlation, although the cell-wise correlations were much lower than G2S3, SAVER, 
scTSSR and EnImpute in all datasets. The other methods, kNN-smoothing, MAGIC, 
scImpute, ALRA and DCA, did not have comparable performance, especially based on the 
gene-wise correlation. SAUCIE did not have comparable performance to the other methods 
in all datasets (Fig S3.2). Since genes with higher expression tend to have a lower dropout 
rate, they are usually easier to impute and have less imputation need than those with lower 
expression [84]. To demonstrate the impact of expression level on the method performance, 
we stratified genes into three subsets based on the proportion of cells expressing them in 
the down-sampled data: widely expressed (>80%, n = 155, 111, 110, respectively), mildly 
expressed (30%-80%, n = 615, 357, 1,902, respectively), and rarely expressed (<30%, n = 
3,148, 1,830, 1,617, respectively). Fig S3.3 shows the gene-wise and cell-wise correlations 
in each gene stratum. We can see that G2S3 improved both gene-wise and cell-wise 
correlations compared to the observed data for widely and mildly expressed genes. 
Moreover, G2S3 achieved the most superior recovery accuracy than the other methods for 
both widely and mildly expressed genes, although SAVER, scTSSR and EnImpute had 
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comparable accuracy for widely expressed genes, suggesting the advantage of borrowing 
information from similar genes over from similar cells. For rarely expressed genes, all 
imputation methods did not improve the correlations compared to the observed data using 
both gene-wise and cell-wise correlation, suggesting that there is insufficient information 
for these genes to be successfully imputed. Overall, G2S3 provided the most accurate 




Figure 3.1. Evaluation of expression data recovery of G2S3 by down-sampling. Performance of 
imputation methods measured by correlation with reference data from the first category of datasets, using 
gene-wise (top) and cell-wise (bottom) correlation. Box plots show the median (center line), interquartile 





3.4.4 Restoration of cell subtype separation 
The second category of datasets was used to assess the performance of imputation 
methods in restoring separation between different cell types. In the Chu dataset, there were 
7 cell types including two undifferentiated human ES cell lines (H1 and H9), human 
foreskin fibroblasts (HF), neuronal progenitor cells (NP), definitive endoderm cells (DE), 
endothelial cells (EC), and trophoblast-like cells (TB). To quantify the performance in 
separating these cell subtypes, we calculated the ratio of average inter-subtype distance to 
average intra-subtype distance using the top 𝐾𝐾 principal components (PCs) of the data 
before and after imputation, for 𝐾𝐾 = 1, … ,50. We also calculated the silhouette coefficient 
that measures how similar cells are to cells from the same cell type compared to other cell 
types. In Fig 3.2, G2S3 and EnImpute had the highest inter/intra-subtype distance ratio and 
silhouette coefficient. Both methods performed better than the raw unimputed data, while 
MAGIC, scImpute, ALRA and DCA performed worse than the raw data. SAUCIE 
performed the worst. These results suggest that G2S3 greatly improved the separation 
between different cell types by enhancing the biologically meaningful information in the 





Figure 3.2. Evaluation of G2S3 in improving cell subtype separation. Average inter/intra-subtype 
distance ratio (top) and silhouette coefficient (bottom) to demonstrate cell subtype separation using the top 
principal components of the raw unimputed and imputed data by each method in the Chu dataset. 
 
To demonstrate the comparison using cell clustering results, we generated uniform 
manifold approximation and projection (UMAP) plots in which cells were colored to 
represent the seven cell types in the original dataset. The normalized mutual information 
(MI) and adjusted rand index (RI) were calculated to measure the consistency between cell 
clustering results and true cell subtype labels. Fig 3.3 shows that the imputed data by G2S3 
and EnImpute had a better separation of all cell subtypes than the raw unimputed data, 
except for H1 and H9 cells. Given that both H1 and H9 are undifferentiated human ES cell 
lines, it is expected that separating them is more difficult due to the relative homogeneity 
of human ES cells compared to the progenitors. In contrast, the other imputation methods 
did not have comparable improvement or even reduced the separation of different cell types. 
98 
 
Specifically, DE cells were mixed with EC and TB cells in the raw data and were not 
separated from the other cell subtypes by all methods except G2S3 and EnImpute. MAGIC 
was able to separate EC, HF and TB cells from each other and the rest of the cell subtypes, 
while SAVER was able to separate EC and HF cells from each other and the rest of the cell 
subtypes. VIPER, ALRA, scTSSR and DCA only separated HF cells from the rest, similar 
to the raw data. The imputed data by kNN-smoothing formed many small clusters. 
scImpute tended to mix different cell types into one cluster. SAUCIE overly smoothed the 
data and was not able to separate any cell types. Based on the two measures of consistency 
between cell clustering results and true cell subtype labels, EnImpute had the best 
separation of the cell subtypes (MI=0.77, RI=0.70) and G2S3 was the second best 
(MI=0.74, RI=0.64), while the other methods did not have comparable performance. 
Notice that EnImpute is an ensemble method that combines imputation results from 
multiple methods, and G2S3 is the only method that achieved comparable performance to 
EnImpute. 
 
Figure 3.3. Plots showing 2D-Visualization of the Chu dataset. UMAP plots of the raw unimputed and 
imputed data by all methods. Cells are colored by true cell subtype labels. The normalized mutual 
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information (MI) and adjusted rand index (RI) are calculated to measure the consistency between cell 
clustering results and true cell subtype labels. 
 
Fig S3.5 demonstrates the expression of two cell subtype marker genes GATA6, a 
marker gene of DE cells, and NANOG, a marker gene of H1/H9 cells [104] across all cells 
in the raw unimputed and imputed data by all methods. The normalized MI and adjusted 
RI that measure the consistency between cell clustering results based on these two marker 
genes and true cell labels for DE and H1/H9 cells were also calculated. We can see that 
G2S3 provided the best separation between H1/H9 cells, DE cells and other cell subtypes. 
Specifically, while the raw data mixed H1/H9 cells with other cell subtypes, G2S3 
successfully recovered the expression of GATA6 and NANOG to better separate DE and 
H1/H9 cell subtypes both from each other and from the other cell subtypes. The cell 
clustering results on the G2S3 imputed data achieved the highest consistency with true cell 
subtype labels, indicating its best performance. None of the other methods had comparable 
performance. DCA separated H1/H9 cells but had DE cells marginally overlapped with 
other cell types. We observed many small clusters of cells after imputation by kNN-
smoothing, similar to the pattern displayed in Fig 3.3. The other methods did not improve 
cell subtype separation compared to the raw data. In addition, the imputed data by VIPER, 
kNN-smoothing and ALRA still had a large proportion of dropout events. These results 
suggest that G2S3 had the best performance in restoring the separation of different cell 
types, preserving biological meaningful variations, and reducing technical noises. 
 
3.4.5 Improvement in cell trajectory inference 
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Reconstruction of cell trajectories using scRNA-seq data is important for investigating 
a dynamic process. However, dropout events may impair pseudo-time inference. We used 
the Petropoulos dataset to evaluate the performance of all imputation methods in cell 
trajectory inference. This dataset consists of human preimplantation embryonic cells from 
five embryonic days (E3-E7) that represent the differentiation stage or age of the 
embryonic cells. We used Monocle 2 to infer pseudo-time from the raw unimputed and 
imputed data by each method [110], and compared to the actual embryonic days of the cells 
for performance evaluation. The pseudotemporal ordering score (POS) and Kendall rank 
correlation coefficient (Cor) were calculated to measure the consistency. Fig 3.4 shows cell 
trajectories in the raw and imputed data by all methods. The cell trajectory plots showed 
the sequential layout of cells from earlier to later embryonic days. The imputed data by 
G2S3, scImpute, VIPER and EnImpute had the highest consistency with the actual 
embryonic days, indicating their best performance among all methods. SAVER, kNN-
smoothing, MAGIC, ALRA and DCA formed the second tier of methods with lower 
consistency. scTSSR performed worse than the raw data. SAUCIE had significantly lower 
consistency (POS=0.07, Cor=0.07) compared to all other methods in cell trajectory 
inference. Furthermore, the trajectory analysis showed an increased heterogeneity among 
cells from later embryonic days, especially starting from embryonic day 5. This was 
consistent with the observation of a significant embryonic cell differentiation event on 





Figure 3.4. Visualization of cell trajectories in the raw and imputed data by all methods. Cells are projected into 
two-dimensional space using reversed graph embedding. Pseudotemporal ordering score (POS) and Kendall rank 
correlation coefficient (Cor) are used to measure the consistency between the actual 
 
3.4.6 Improvement in differential expression analysis 
One common analytical task for scRNA-seq studies is to identify genes differentially 
expressed between cells from two groups of subjects or two cell types. In this section, we 
used two datasets to evaluate and compare the improvement in downstream differential 
expression analysis before and after imputation by all methods: the Chu dataset of different 
cell types and the Trapnell dataset of differentiating human myoblasts. Besides the scRNA-
seq data, both datasets provide bulk RNA-seq data on the same samples. The differentially 
expressed genes identified from the bulk RNA-seq data were treated as ground truth. We 
assessed the predictive power of the scRNA-seq data imputed by different methods on the 
ground truth using receiver operating characteristic (ROC) curves. 
In the Chu dataset, we identified marker genes that differentiate the two cell types: NP 
and H1 cells. Fig 3.5A shows that G2S3 had the highest area under the curve (AUC) in 
detecting differentially expressed genes. kNN-smoothing, DCA and EnImpute had an AUC 
score lower than G2S3 but higher than the raw data. The other methods had comparable 
performance to the raw data except MAGIC, which had the lowest AUC. This is likely due 
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to the fact that a small cluster of NP cells were mixed with H1 cells after imputation by 
MAGIC (Fig 3.3), resulting in compromised performance in marker gene identification. 
Our results were largely consistent with a previous evaluation of imputation methods in 
identifying differentially expressed genes using Fluidigm C1 data [113]. No genes 
achieved significance in the imputed data by SAUCIE so the result of SAUCIE could not 
be shown. In the Trapnell dataset, we performed differential expression analysis between 
undifferentiated primary human myoblasts and mature myotubes captured 72 hours after 
inducing differentiation. Fig 3.5B shows that G2S3 achieved the highest AUC indicating 
its best performance, followed by VIPER. kNN-smoothing and DCA had much worse 
performance than the raw data. No genes achieved significance in the imputed data by 
MAGIC and SAUCIE so their results could not be shown. Altogether, the results from both 
datasets showed that G2S3 had the best improvement in the downstream differential 
expression analysis. 
 
Figure 3.5. Receiver operating characteristic (ROC) curves demonstrating improvement in 
differential expression analysis. ROC curves of the scRNA-seq differential expression results predicting 
differentially expressed genes identified in the bulk RNA-seq data on the same samples in the Chu (A) and 




3.4.7 Gene correlation relationship recovery 
We compared the method performance in recovering gene correlation relationships 
using two scRNA-seq dastasets. In the Paul dataset, we examined the pairwise correlation 
between well-known transcription factors in the development of blood cells before and 
after imputation [111]. In the Buettner dataset, we investigated the relationships among a 
set of 67 periodic marker genes before and after imputation, in which 16 genes have peak 
expression in the G1/S phase and 51 genes have peak expression in the G2/M phase [108]. 
In the Paul dataset, the regulatory relationship among key regulators of the 
transcriptional differentiation of megakaryocyte/erythrocyte progenitors and 
granulocyte/macrophage progenitors in the raw data and the imputed data by each method 
were used for performance evaluation. The gene regulatory network (GRN) of these 
regulators was established in a previous study based on biological experiments [114–116] 
and served as the ground truth. We reconstructed GRNs by two methods, GENIE3 [117] 
and PPCOR [118], in the raw and imputed datasets. The inferred GRNs were compared to 
the ground-truth network using the area under the precision-recall curve (AUPRC). For 
each imputation method, we reported the AUPRC ratio (AUPRC divided by that of a 
random predictor) with 50 replications. Fig 3.6 demonstrates that G2S3 achieved the 
highest AUPRC ratio, followed by kNN-smoothing, using both GRN inference methods. 
The AUPRC ratios of GRNs inferred from the imputed data by either MAGIC or SAUCIE 
were much lower than that from a random predictor, suggesting that the gene regulatory 




Figure 3.6. Performance of G2S3 in recovering gene regulatory relationship. Boxplots showing the 
area under the precision-recall curve (AUPRC) ratios that measure the accuracy of inferred GRNs using the 
imputed data by different imputation methods. Both GENIE3 (top) and PPCOR (bottom) were used to infer 
GRNs. Red line indicates the performance of a random predictor. 
 
We also examined the pairwise correlations between these key regulators. Based on 
previous studies [114–116],  inhibitory and activatory gene pairs were defined, among 
which inhibitory pairs were expected to have negative correlation while activatory pairs 
were expected to have positive correlation. The mutually inhibitory pairs of genes include 
Fli1 vs. Klf1, Egr1 vs. Gfi1, Cebpa vs. Gata1, and Sfpi1 vs. Gata1; and the mutually 
activatory pairs include Sfpi1 vs. Cebpa, Zfpm1 vs. Gata1, Klf1 vs. Gata1. Fig S3.6 shows 
that most of the methods were able to enhance the pairwise correlations after imputation in 
the correct direction. Overall, G2S3 and SAVER showed the greatest enhancement of 
pairwise correlation for both inhibitory and activatory pairs, followed by kNN-smoothing 
and EnImpute. Although MAGIC intensified the pairwise correlations, most activatory 
pairs had correlations close to 1 after imputation. ALRA and DCA strengthened the 
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pairwise correlation for activatory pairs but did not improve much for inhibitory pairs. 
Imputation by SAUCIE resulted in all gene pairs to be highly positively correlated.  
In the Buettner dataset, we expect pairs of periodic genes whose expression peak in the 
same phase of cell cycle to be positively correlated and those that peak during different 
phases to be negatively correlated. There are 67 marker genes for G1/S and G2/M phases 
[111]. We examined the correlation of all 2,211 marker gene pairs in the raw data and 
imputed data by each method. The proportion of gene pairs whose correlations are in the 
correct direction was used for performance comparison. Table 3.2 shows that all methods 
had comparable performance in maintaining a high proportion of positively correlated gene 
pairs, whereas their performance varies in restoring negatively correlated gene pairs. G2S3, 
SAVER and EnImpute were able to recover 28% or more of the negatively correlated gene 
pairs. All gene pairs became positively correlated after imputation by MAGIC, scImpute, 
VIPER, ALRA, DCA and SAUCIE, thus no negative correlation was observed after 
imputation. Similar observations were found in a previous study in which some of these 
methods introduced a large number of positive gene correlations after imputation, many of 
which may be spurious [90]. 
 
Table 3.2. Fraction of periodic gene pairs with correct direction of correlation in the raw and 
imputed data by each method 
Imputation Methods Positive Pairs Negative Pairs 
Raw 1.00 0.00 
G2S3 0.91 0.32 
SAVER 0.94 0.28 
kNN-smoothing 0.97 0.17 
MAGIC 1.00 0.00 
scImpute 1.00 0.00 
VIPER 1.00 0.00 
ALRA 1.00 0.00 
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scTSSR 0.98 0.11 
DCA 1.00 0.00 
SAUCIE 1.00 0.00 
EnImpute 0.91 0.46 
 
In summary, the results from both datasets suggested that G2S3 enhanced gene-gene 
relationships especially for negatively correlated gene pairs in which the expression of one 
gene is inhibited by the other. As lowly expressed genes are in general harder to impute, 
negatively correlated relationship is a harder task for imputation to restore the correlated 
relationship. 
3.4.8 Summary of method performance 
We evaluated and compared the performance of G2S3 and the other ten imputation 
methods using five evaluation criteria corresponding to five downstream analyses of 
scRNA-seq data. Fig 3.7 summarizes the overall performance of all methods. G2S3 was 
ranked first in three out of the five evaluation criteria, second in cell clustering, and third 
in cell trajectory inference. For those criteria under which G2S3 did not achieve the best 
performance, it had close or comparable performance to the best method. No other method 
achieved the best performance in as many criteria as that of G2S3. Overall, G2S3 




Figure 3.7. Summary of performance of G2S3 and other imputation methods. A heatmap 
demonstrating the method performance based on the five evaluation criteria. The left five columns display 
performance rank using each of the five evaluation criteria. The rightmost column displays the overall 
performance rank based on the sum of all five ranks. 
 
 
3.4.9 Computation time 
While SAVER and EnImpute have comparable performance to G2S3 in some datasets, 
G2S3 is computationally more efficient (Table 3.3). Since both G2S3 and SAVER are gene 
network-based imputation methods, their computation time is expected to increase with the 
number of genes to be imputed. This makes gene network-based methods more suitable 
than those based on cell similarity for large scRNA-seq datasets with tens or even hundreds 
of thousands of cells. In real data analysis, G2S3 was on average about twenty times faster 
108 
 
than SAVER. EnImpute is an ensemble method that relies on imputation results from 
multiple methods and therefore takes longer time than SAVER. On the other hand, the 
computation time of imputation methods that borrow information from similar cells 
increases dramatically with the number of cells in the data. As demonstrated in a previous 
study, scImpute and VIPER were unable to scale beyond 10K cells within 24 hours [95]. 
In our assessment, VIPER takes about two days to impute the down-sampled datasets with 
several thousands of genes while other methods finish within several minutes. 
Table 3.3. Computational Time for Each Imputation Methods. Running time in minutes for each 
imputation task among imputation methods using a single processor on an 8-core, 50 GB RAM, Intel Xeon 











Reyfman 4.27 60.12 0.25 0.35 29.46 5289.17 0.16 9.80 5.40 0.86 102.23 
Zeisel 2.99 43.26 0.18 0.24 70.67 3618.86 0.10 4.26 4.27 0.74 121.84 
PBMC 1.09 25.91 0.15 0.17 17.77 524.37 0.08 3.48 2.78 0.98 50.84 
 
3.5 Discussion 
We have developed a novel method G2S3 to impute dropouts in scRNA-seq data. G2S3 
learns a sparse and smooth signals of gene graph from scRNA-seq data and borrows 
information from nearby genes in the graph for imputation. We evaluated and compared 
the performance of G2S3 and ten existing imputation methods in terms of recovering true 
expression levels, restoring cell subtype separation, reconstructing cell trajectory, 
identifying differentially expressed genes, and restoring gene correlation relationships 
using eight scRNA-seq datasets. The results demonstrated that G2S3 achieved superior 
performance or had comparable performance to other methods based on the five evaluation 
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criteria above, especially for genes with relatively low expression. Furthermore, G2S3 is 
the most computationally efficient method for large-scale scRNA-seq data imputation. 
Unlike imputation methods that borrow information across similar cells, G2S3 
harnesses the structural relationship among genes obtained through graph signal processing 
to perform imputation. Using eight real datasets, we showed that methods relying on cell 
similarity tend to remove biological variation among cells and intensify subject-level batch 
effects. In contrast, G2S3 enhances cell subtype separation and thus relatively reduces 
variations in cells from the same cell type and subject. The down-sampling and differential 
expression analysis results showed that G2S3 outperformed the other methods, especially 
for lowly expressed genes. Of note, imputation methods such as SAVER, scImpute and 
VIPER, used parametric models for gene expression. However, as the noise distribution 
varies across different scRNA-seq platforms, assumptions of the parametric models may 
be violated, particularly for new technologies. Graph signal processing extracts signals 
from data by optimizing a smoothness regulated objective function, so it is in principle less 
sensitive to the noise distribution. To our knowledge, there are two imputation methods 
that use gene graph/network for imputation in scRNA-seq data, published during the 
preparation of this manuscript: netNMF-sc [119] uses network-regularized non-negative 
matrix factorization to leverage gene-gene interactions for imputation; and netSmooth [120] 
incorporates protein-protein interaction networks to smooth gene expression values. Both 
methods require prior information on gene-gene interactions from RNA-seq or microarray 
studies of bulk tissue. In contrast, G2S3 learns gene network structure in an unbiased way 
from scRNA-seq data. In our experiments, G2S3 had comparable performance to EnImpute, 
an ensemble learning method that combines results from multiple imputation methods. 
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G2S3 learns gene-gene relationship by optimizing a sparse gene graph and at the same 
time allows expression levels to change smoothly between closely connected genes. Since 
many gene networks and biochemical networks are sparse [110,121,122], the sparsity 
property is important for inferring gene network. There are several methods available for 
constructing gene network, many of them are kernel-based, which result in full weight 
matrices where sparsity has to be imposed afterwards, for example, thresholding the 
adjacency weights. We found that top eigenvectors of graph Laplacian on the gene 
networks learned from Gaussian kernel were highly correlated with dropout rate, 
suggesting that dropout events tend to bias the construction of gene network in scRNA-seq 
data. G2S3 algorithm uses one step random walk to avoid over-smoothing because multiple 
steps of the random walk tended to overly smooth data and leaded to worse performance. 
Similar observations were reported in another manuscript discussing parameter tuning for 
diffusion-based imputation methods for scRNA-seq data [112]. It showed that for many 
diffusion-based methods including MAGIC, single step (t=1) yielded better performance 
than multiple steps or iterations until convergence. For UMI-based datasets, to account for 
the effect of varying sequencing depths, we recommend normalizing UMI counts before 
applying G2S3 for more accurate construction of gene graph and imputation of expression 
levels. 
Despite the advantages of G2S3 over the other imputation methods shown in this article, 
G2S3 can be improved in several directions. First, G2S3 uses a lazy random walk on the 
gene graph to recover dropout events, i.e., weighted average of the observed expression of 
the gene of interest and that from neighboring genes. The weights currently depend only 
on between gene similarity which can be improved by considering the reliability of 
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observed read counts, cell library size, and dispersion of gene expression, similar to the 
weights used in SAVER. Second, G2S3 does not consider dropout rate and therefore 
imputes all values at once. This can be improved by calculating the probability of being a 
dropout for each observed read count and only performing imputation on those with a high 
dropout probability. Third, the G2S3 model can be improved by adding two tuning 
parameters for the second and third terms in the objective function that control the degree 
of smoothness and sparsity of the resulting gene network. The tuning parameters can be 
chosen based on the complexity and structure of scRNA-seq data. Finally, G2S3 does not 
consider the potential subject effect in the data, which has been shown to be prevalent and 
dominant in certain cell types. One way to address this issue is to consider subject effect 
as “batch” effect and remove it using batch effect removal tools. This is effective only 
when there are no other effects of interest confounding the subject effect, for example, 
disease effect, because they will also be removed together with “batch” effect. When there 
are other effects that confound with subject effect and are the interest of study, G2S3 can 







S 2.1 Quasi-likelihood score of 𝜸𝜸 
The quasi-likelihood score function for 𝜸𝜸 can be written as 
𝑼𝑼(𝜸𝜸) = (𝐈𝐈𝑚𝑚 ⊗𝚽𝚽𝑨𝑨)𝑇𝑇(𝚺𝚺𝐺𝐺 ⊗𝚽𝚽)−1�𝑮𝑮� − 2𝒑𝒑⊗ 𝟏𝟏𝑛𝑛 − 𝜸𝜸⊗𝚽𝚽𝑨𝑨�
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= 𝚺𝚺𝐺𝐺−1𝑮𝑮𝑇𝑇𝑨𝑨 − (𝑨𝑨𝑇𝑇𝚽𝚽𝑨𝑨)𝚺𝚺𝐺𝐺−1𝜸𝜸. 
The last equation holds because 𝑨𝑨𝑇𝑇𝟏𝟏𝑛𝑛 = 0 and (𝚺𝚺𝐺𝐺−1 ⊗ 𝑨𝑨)𝑇𝑇𝑮𝑮� = 𝚺𝚺𝐺𝐺−1𝑮𝑮𝑇𝑇𝑨𝑨. 
 
S 2.2 Covariance of 𝑮𝑮𝑇𝑇𝑨𝑨 
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Figure S3.1 Comparison of the mean-variance relationship in gene expression before and after down-
sampling. For each gene, the coefficient of variation (CV) across all cells after down-sampling (y-axis) is 






Figure S3.2 Optimal value of hyperparameter in G2S3. A. Mean squared error (MSE) at different 
diffusion steps in three down-sampled datasets. B. Gene-wise and cell-wise correlations of G2S3 imputed 




Figure S3.3 Evaluation of expression data recovery of all imputation methods by down-sampling. 
Performance of imputation methods measured by correlation with reference data from the first category of 
datasets, using gene-wise (top) and cell-wise (bottom) correlation. Box plots show the median (center line), 






Figure S3.4 Evaluation of expression data recovery of all imputation methods by down-sampling in 
three gene strata. Performance of imputation methods measured by correlation with reference data from 
the first category of datasets, using gene-wise (top) and cell-wise (bottom) correlation. Genes are stratified 
into three groups: widely (>80%, left), mildly (30%-80%, middle), and rarely (<30%, right) expressed. 
 
 
Figure S3.5 Cell subtype marker gene expression in the Chu dataset. Scatter plot showing expression 







Figure S3.6 Evaluation of recovering gene correlation relationship of all imputation methods in the 
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